Integris Medtech Limited - Addendum to DRHP

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF BSE LIMITED (“BSE”) AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE”, AND TOGETHER WITH BSE, THE “STOCK EXCHANGES”) IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (“SEBI ICDR REGULATIONS”) (Please scan this QR code to view the DRHP and this Addendum) INTEGRIS MEDTECH LIMITED (FORMERLY KNOWN AS INTEGRIS HEALTH PRIVATE LIMITED) Our Company was incorporated as ‘Integris Health Private Limited’ as a private limited company under Companies Act, 1956 pursuant to certificate of incorporation dated April 25, 2008, issued by Assistant Registrar of Companies, National Capital Territory of Delhi and Haryana at Delhi. Our Company changed its name to ‘Integris Medtech Private Limited’, pursuant to which a fresh certificate of incorporation dated June 30, 2025 was issued by the Assistant Registrar of Companies, Central Processing Centre. Further, our Company was converted into a public limited company pursuant to the resolution passed by our Board of Directors on July 16, 2025, and special resolution passed by our Shareholders on August 1, 2025 and the name of our Company was changed to ‘Integris Medtech Limited’ and consequently, a fresh certificate of incorporation dated August 8, 2025 was issued by the Assistant Registrar of Companies, Central Processing Centre. For further details in relation to the changes in the name and registered office of our Company, see “History and Certain Corporate Matters” on page 305 of the DRHP.

Registered Office: 1st Floor, Metro Tower LSC, M.O.R Land, New Rajinder Nagar, New Delhi, 110 060 Delhi, India

Corporate Office: 15th Floor, One Horizon Center, Golf Course Road, DLF Phase 5, Sector 43, Gurgaon 122002, Haryana, India

Tel: +91 124 4673710; Website: www.integrismedtech.com; Contact person: Darpan Batra, Group General Counsel, Company Secretary and Compliance Officer E-mail: investors@integrismedtech.com; Corporate Identity Number: U85110DL2008PLC177230 NOTICE TO INVESTORS ADDENDUM TO THE DRAFT RED HERRING PROSPECTUS DATED OCTOBER 9, 2025 (THE “ADDENDUM” AND SUCH DRAFT RED HERRING PROSPECTUS, THE “DRAFT RED HERRING PROSPECTUS” OR THE “DRHP”)

PROMOTERS OF OUR COMPANY: EVERCURE HOLDINGS PTE. LTD., MEDICORE HOLDINGS PTE. LTD., GURMIT SINGH CHUGH AND PUNITA SHARMA INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH (“EQUITY SHARES”) OF INTEGRIS MEDTECH LIMITED (FORMERLY KNOWN AS INTEGRIS HEALTH PRIVATE LIMITED) (OUR “COMPANY” OR THE “COMPANY”) FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹[●] PER EQUITY SHARE) (“OFFER PRICE”) AGGREGATING UP TO ₹[●] MILLION (THE “OFFER”) COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹6,000.00 MILLION (THE “FRESH ISSUE”) AND AN OFFER FOR SALE (THE “OFFER FOR SALE”) OF UP TO 10,837,266 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY EVERCURE HOLDINGS PTE. LTD., (THE “PROMOTER SELLING SHAREHOLDER” AND SUCH SHARES, THE “OFFERED SHARES”).

THE FACE VALUE OF EQUITY SHARES IS ₹1 EACH. THE OFFER PRICE IS [●] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT SHALL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, AND WILL BE ADVERTISED IN ALL EDITIONS OF FINANCIAL EXPRESS, AN ENGLISH NATIONAL DAILY NEWSPAPER AND ALL EDITIONS OF JANSATTA, A HINDI NATIONAL DAILY NEWSPAPER (HINDI ALSO BEING THE REGIONAL LANGUAGE OF DELHI, WHERE OUR REGISTERED OFFICE IS LOCATED) EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO THE STOCK EXCHANGES FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SEBI ICDR REGULATIONS.

This Addendum is in reference to the DRHP filed with the Securities and Exchange Board of India (“SEBI”) and the Stock Exchanges. In this regard, potential investors should note that in accordance with the SEBI ICDR Regulations and the guidance provided by SEBI pursuant to its email dated April 13, 2026 read with its email dated October 12, 2026 to the Association of Investment Bankers of India permitting issuers to increase or decrease the fresh issue size by up to 50%, without re-filing the draft red herring prospectus for all initial public offerings opening on or before March 31, 2027 (the “SEBI Communication”), and pursuant to Board resolution dated October 19, 2026, our Company has decided to reduce the size of the fresh issue in the Offer from INR 9,250 million as disclosed in the DRHP to INR 6,000 million (i.e. within the permissible limit of up to 50%) due to evolving market dynamics resulting from heightened volatility arising from external geopolitical developments. Further, our Company has received (i) letters from Gurmit Singh Chugh and Punita Sharma, each dated October 18, 2026, who had earlier consented to participate as selling shareholders in the Offer for Sale, informing our Company of their decision to withdraw the offer of their portion of the Offered Shares in the Offer, and (ii) consent letter dated October 19, 2026 from Evercure Holdings Pte. Ltd. informing our Company of its decision to decrease its portion of the Offered Shares in the Offer for Sale to up to 10,837,266 Equity Shares. Accordingly, the Offer size has been revised and disclosed through this Addendum. All references to the Fresh Issue size, Offer for Sale and the overall Offer size in the DRHP shall be revised and modified at all applicable places in the Red Herring Prospectus, the Abridged Prospectus, and Prospectus, as applicable.

Potential investors may note that in order to assist the investors to get a complete understanding of the updated information, the sections titled “The Offer” and “Objects of the Offer” beginning on pages 80 and 116 respectively, of the DRHP, have been appropriately updated only to reflect changes related to the updated Fresh Issue size, Offer for Sale and the Offer size and included in this Addendum to reflect, inter alia, the above modifications.

Accordingly, the required updates and amendments to the portions of the cover page and sections titled “Definitions and Abbreviations”, “The Offer”, “Capital Structure”, “Objects of the Offer” and “Offer Structure” beginning on pages 1, 80, 98, 116 and 571 respectively, of the DRHP, will be updated in the Red Herring Prospectus, Abridged Prospectus, and Prospectus, as applicable.

The changes conveyed by way of this Addendum are to be read in conjunction with the DRHP and, accordingly, the corresponding references in the DRHP stand updated pursuant to this Addendum. The information in this Addendum supplements and updates the information in the DRHP, as applicable, and accordingly henceforth any reference to the DRHP shall be a reference to the DRHP read with this Addendum. However, this Addendum does not purport to, nor does it, reflect all the changes that have occurred from the date of filing of the DRHP and till the date of this Addendum. Accordingly, this Addendum does not include all the changes and/or updates that will be included in the Red Herring Prospectus and/or the Abridged Prospectus and/or the Prospectus as and when filed with the Registrar of Companies, National Capital Territory of Delhi – II at Delhi (“RoC”), the SEBI and the Stock Exchanges. Please note that the information included in the DRHP will be suitably updated, including to the extent stated/ updated by way of this Addendum, as may be applicable, in the Red Herring Prospectus, the Abridged Prospectus, and the Prospectus. Investors should not rely on the DRHP or this Addendum for any investment decision, and should read the Red Herring Prospectus, as and when it is filed with the RoC, SEBI and the Stock Exchanges before making an investment decision with respect to the Offer.

This Addendum which has been filed with SEBI and the Stock Exchanges and shall be available on the website of SEBI at www.sebi.gov.in, the website of Stock Exchanges at www.nseindia.com and www.bseindia.com, the website of our Company at www.integrismedtech.com and the websites of the Book Running Lead Managers, namely, ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited, and IIFL Capital Services Limited (formerly known as IIFL Securities Limited) on www.icicisecurities.com, www.axiscapital.co.in, www.citigroup.com/global/about-us/global-presence/india/disclaimer, and www.iiflcapital.com, respectively. Unless stated otherwise, all references to page numbers in this Addendum are to the page numbers of the DRHP. All capitalized terms used in this Addendum shall, unless the context otherwise requires, have the meanings ascribed to them in the DRHP.

Place: Gurugram, India For Integris Medtech Limited

Date: October 19, 2026 On behalf of the Board of Directors Sd/- Darpan Batra Group General Counsel, Company Secretary and Compliance Officer BOOK RUNNING LEAD MANAGERS REGISTRAR TO THE OFFER ICICI Securities Limited Axis Capital Limited Citigroup Global Markets India IIFL Capital Services Limited KFin Technologies Limited ICICI Venture House 1st Floor, Axis House Private Limited (formerly known as IIFL Securities Selenium Tower B, Plot No. 31 and 32 Appasaheb Marathe Marg Pandurang Budhkar Marg, Worli 1202, 12th Floor, First International Limited) Financial District, Nanakramguda Prabhadevi, Mumbai 400 025 Mumbai 400 025 Financial Centre (FIFC) 24th Floor, One Lodha Place Serilingampally Maharashtra, India Maharashtra, India G-Block, Bandra Kurla Complex, Senapati Bapat Marg, Lower Parel Hyderabad - 500 032

Tel: +91 22 6807 7100 Tel: + 91 22 4325 2183 Bandra East (West) Telangana, India

Email: E-mail: integris.ipo@axiscap.in Mumbai 400 098 Mumbai 400 013 Tel: +91 406716 2222/ 18003094001 integris.ipo@icicisecurities.com Website: www.axiscapital.co.in Maharashtra, India Maharashtra, India E-mail: integris.ipo@kfintech.com

Website: www.icicisecurities.com Investor Grievance ID: Tel: +91 22 6175 9999 Tel: +91 22 4646 4728 Investor Grievance ID:

Investor Grievance ID: complaints@axiscap.in E-mail: integrismedtech.ipo@citi.com E-mail: integris.ipo@iiflcap.com einward.ris@kfintech.com customercare@icicisecurities.com Contact person: Tosit Agarwal Investor Grievance ID: Investor Grievance ID: Website: www.kfintech.com

Contact person: Tanya Tiwari/ SEBI Registration No.: investors.cgmib@citi.com ig.ib@iiflcap.com Contact person: Williams R Ramesh Vaswana INM000012029 Website: Website: www.iiflcapital.com SEBI Registration No.:

SEBI registration No.: https://www.citigroup.com/global/abou Contact person: Yogesh Malpani / INR000000221 INM000011179 t-us/global-presence/india/disclaimer Pawan Kumar Jain

Contact person: Adarsh Agarwal SEBI Registration No.:

SEBI Registration No.: INM000010940 INM000010718 BID/OFFER PERIOD ANCHOR INVESTOR [●] BID/OFFER OPENS ON [●] BID/OFFER CLOSES [●] BID/OFFER PERIOD* ON**^ * Our Company may in consultation with the Book Running Lead Managers, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Offer Opening Date.

** Our Company, in consultation with the Book Running Lead Managers, may consider closing the Bid/Offer Period for QIBs one Working Day prior to the Bid/Offer Closing Date in accordance with the SEBI ICDR Regulations.Integris Medtech Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP dated October 9, 2025 with SEBI and the Stock Exchanges. The DRHP is available on the website of SEBI at www.sebi.gov.in, the website of Stock Exchanges at www.nseindia.com and www.bseindia.com, the website of our Company at www.integrismedtech.com and the websites of the Book Running Lead Managers, namely, ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited, and IIFL Capital Services Limited (formerly known as IIFL Securities Limited) on www.icicisecurities.com, www.axiscapital.co.in, www.citigroup.com/global/about-us/global-presence/india/disclaimer, and www.iiflcapital.com, respectively. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled “Risk Factors” on page 34 of the DRHP and the details set out in the RHP, when filed. Potential investors should not rely on the DRHP filed with SEBI and Stock Exchanges and should rely on the RHP, for making any investment decision.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Offer have not been and will not be registered under the United States Securities Act of 1933, as amended ("U.S. Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in ‘offshore transactions’ as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.TABLE OF CONTENTS THE OFFER ....................................................................................................................................................... 4 OBJECTS OF THE OFFER .............................................................................................................................. 6 DECLARATION .............................................................................................................................................. 38THE OFFER

The following table summarizes the Offer details:

Offer of Equity Shares(1)(2) Up to [●] Equity Shares of face value ₹1 each, aggregating up to ₹[●] million of which Fresh Issue(1) Up to [●] Equity Shares of face value ₹1 each, aggregating up to ₹6,000.00 million Offer for Sale(2) Up to 10,837,266 Equity Shares of face value ₹1 each, aggregating up to ₹[●] million

The Offer consists of:

A) QIB Portion(3)(4) Not less than [●] Equity Shares of face value ₹1 each, aggregating up to ₹[●] million

of which:

Anchor Investor Portion Up to [●] Equity Shares of face value ₹1 each of which 40% of the Anchor Investor Portion shall be reserved in the

following manner: - 33.33% of the Anchor Investor Portion shall be reserved for Up to [●] Equity Shares of face value of ₹1 each allocation to domestic Mutual Funds - 6.67% of the Anchor Investor Portion shall be reserved for Up to [●] Equity Shares of face value of ₹1 each allocation to Life Insurance Companies and Pension Funds Net QIB Portion (assuming Anchor Investor Portion is fully [●] Equity Shares of face value ₹1 each subscribed)

of which:

Available for allocation to Mutual Funds only (5% of the Net QIB [●] Equity Shares of face value ₹1 each Portion) Balance of QIB Portion for all QIBs including Mutual Funds [●] Equity Shares of face value ₹1 each B) Non-Institutional Portion(3)(5) Not more than [●] Equity Shares of face value ₹1 each, aggregating up to ₹[●] million

of which:

One-third of the Non-Institutional Portion available for allocation to [●] Equity Shares of face value ₹1 each Bidders with an application size of more than ₹0.20 million and up to ₹1.00 million Two-thirds of the Non-Institutional Portion available for allocation [●] Equity Shares of face value ₹1 each to Bidders with an application size of more than ₹1.00 million C) Retail Portion(3) Not more than [●] Equity shares of face value ₹1 each, aggregating up to ₹[●] million Pre-Offer and post-Offer Equity Shares Equity Shares outstanding prior to the Offer (as on the date of this 108,338,049 Equity Shares of face value ₹1 each Draft Red Herring Prospectus) Equity Shares outstanding after the Offer [●] Equity Shares of face value ₹1 each Use of Net Proceeds of the Offer See “Objects of the Offer” beginning on page [●] for details regarding the use of Net Proceeds

(1) Our Board has authorized the Offer pursuant to its resolution dated September 22, 2025, read with the resolution dated October 19, 2026, and the Fresh Issue has been authorised by our Shareholders, pursuant to their special resolution dated September 29, 2025.

(2) Our Board has pursuant to its resolution dated October 19, 2026 taken on record the consent of Promoter Selling Shareholder to participate in the Offer for Sale in relation to the Offered Shares. The Promoter Selling Shareholder has authorised its participation in the Offer for Sale for the Offered Shares,

as set out below:

S. Promoter Selling Number of Offered Shares* Aggregate proceeds Date of board resolution/ Date of consent letter No. Shareholder from the Offered Shares corporate authorisation

1. E vercure Holdings Pte. Ltd. Up to 10,837,266 Equity Shares Up to ₹[●] million September 29, 2025 October 19, 2026 of face value of ₹1 each * The Promoter Selling Shareholder, has confirmed its eligibility to participate in the Offer for Sale in accordance with Regulation 8 of the SEBI ICDR Regulations. Further, the Promoter Selling Shareholder confirms that the Offered Shares will be offered for sale in the Offer in accordance with Regulation 8A of the SEBI ICDR Regulations, to the extent applicable to the Promoter Selling Shareholder. For details of authorisations for the Offer for Sale, see “Other Regulatory and Statutory Disclosures – Authority for the Offer” on page [●].

(3) Subject to valid Bids being received at or above the Offer Price, under-subscription, if any, in any category except the QIB Portion, would be allowed to be met with spill-over from any other category or combination of categories of Bidders at the discretion of our Company, in consultation with the Book 4Running Lead Managers, and the Designated Stock Exchange, subject to applicable laws. Under-subscription, if any, in the QIB Portion (excluding the Anchor Investor Portion) will not be allowed to be met with spill-over from other categories or a combination of categories.

(4) Our Company, in consultation with the Book Running Lead Managers may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis of which 40% of the Anchor Investor Portion shall be reserved in the following manner: (a) 33.33% shall be reserved for domestic Mutual Funds;

and (b) 6.67% shall be reserved for Life Insurance Companies and Pension Funds, subject to valid bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription or non-Allotment in the Anchor Investor Portion, the remaining Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than [●] Equity Shares of face value ₹1 each, the balance Equity Shares available for allotment in the Mutual Fund Portion will be added to the Net QIB Portion and allocated proportionately to the QIB Bidders (other than Anchor Investors) in proportion to their Bids. For details, see “Offer Procedure” beginning on page [●]. Allocation to all categories shall be made in accordance with the SEBI ICDR Regulations.

(5) The Equity Shares available for allocation to Non-Institutional Bidders under the Non-Institutional Portion, shall be subject to the following: (i) one- third of the portion available to Non-Institutional Bidders shall be reserved for applicants with an application size of more than ₹0.20 million and up to ₹1.00 million, and (ii) two-third of the portion available to Non-Institutional Bidders shall be reserved for applicants with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of the aforementioned sub-categories may be allocated to applicants in the other sub- category of Non-Institutional Bidders. The allotment to each Non-Institutional Bidder shall not be less than the minimum application size, subject to the availability of Equity Shares in the Non-Institutional Portion, and the remaining Equity Shares, if any, shall be allotted on a proportionate basis.

Allocation to Bidders in all categories except the Anchor Investor Portion, Non-Institutional Portion and the Retail Portion, if any, shall be made on a proportionate basis subject to valid Bids received at or above the Offer Price. The allocation to each of the RIBs shall not be less than the minimum Bid Lot, subject to availability of Equity Shares in the Retail Portion and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis. Allocation to Anchor Investors shall be on a discretionary basis in accordance with the SEBI ICDR Regulations. For further details, see “Offer Procedure” beginning on page [●].

For details of the terms of the Offer, see “Terms of the Offer” beginning on page [●].

5OBJECTS OF THE OFFER Offer comprises the Fresh Issue of up to [●] Equity Shares of face value ₹1 each aggregating up to ₹ 6,000.00 million and the Offer for Sale of up to 10,837,266 Equity Shares of face value ₹1 each aggregating up to ₹ [●] million, cumulatively aggregating up to ₹ [●] million.

Offer for Sale The object of the Offer for Sale is to allow the Promoter Selling Shareholder to sell an aggregate of up to 10,837,266 Equity Shares having face value of ₹ 1 each aggregating up to ₹ [●] million held by them. The Promoter Selling Shareholder shall be entitled to the proceeds of the Offer for Sale, after deducting its proportion of the Offer-related expenses and the relevant taxes thereon, in accordance with the terms of the Offer Agreement. For further details, see “ - Offer expenses” on page [●]. Our Company will not receive any proceeds from the Offer for Sale and the proceeds received from the Offer for Sale will not form part of the Net Proceeds. For further details of the Offer for Sale, see “The Offer” on page [●].

The Promoter Selling Shareholder has authorised its participation in the Offer for Sale to the extent of the Offered Shares, pursuant to their respective consent letters, as set out below. For details, see “The Offer” on page [●].

S. No. Promoter Selling Number of Offered Shares Aggregate Date of board Date of consent Shareholder proceeds from resolution/ corporate letter the Offered authorisation Shares*

1. Evercure Holdings Pte. Up to 10,837,266 Equity Shares Up to ₹[●] million September 29, 2025 October 19, 2026 Ltd. of face value of ₹1 each *To be determined upon finalisation of the Offer Price and updated in the Prospectus prior to filing with the RoC.

Objects of the Fresh Issue

Our Company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:

1. Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: a. Our wholly-owned Subsidiaries, namely, Translumina Therapeutics Private Limited (“Translumina Therapeutics”) and Transhealth Private Limited (“Transhealth”) ; and b. Our step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd.

2. General corporate purposes. (collectively, the “Objects”, and individually, each an “Object”).

Further, our Company expects to receive the benefits of listing of the Equity Shares on the Stock Exchanges, including enhancement of our Company’s brand name and creation of a public market for our Equity Shares in India.

The main objects and objects incidental and ancillary to the main objects set out in the Memorandum of Association enable us:

(i) to undertake our existing business activities; and (ii) to undertake the activities for which the funds are being raised by us in the Fresh Issue and are proposed to be funded from the Net Proceeds.

Net Proceeds After deducting our Company’s share of the Offer related expenses from the Gross Proceeds received pursuant to the Fresh Issue, we estimate the net proceeds to be ₹[●] million (“Net Proceeds”), as set out in the table below:

(in ₹ million) Particulars Estimated amount Gross Proceeds of the Fresh Issue* 6,000.00

(Less) Offer related expenses in relation to the Fresh Issue^ []* Net Proceeds* []* *To be determined upon finalisation of the Offer Price and updated in the Prospectus prior to filing with the RoC. ^ For details of the expenses related to the Offer, see “- Offer Expenses” on page [●] 6Requirement of funds and utilization of Net Proceeds

The Net Proceeds are proposed to be utilized in accordance with the details set out in the table below:

Sr. No. Particulars Amount (₹ million)

1. Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and 5,098.51 prepayment penalties, as applicable, availed by: a. Our wholly-owned Subsidiaries, namely, Translumina Therapeutics and Transhealth 938.74 b. Our step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd.. and 4,159.77 Research Instruments Pte. Ltd.

2. General corporate purposes^* [●] Net Proceeds* [●] ^ The amount to be utilised for general corporate purposes shall not exceed 25% of the Gross Proceeds. * To be determined upon finalisation of the Offer Price and Offer Expenses and shall be updated in the Prospectus prior to filing with the RoC.

Proposed schedule of implementation and deployment of Net Proceeds We propose to deploy the Net Proceeds towards the Objects in accordance with the estimated schedule of implementation and

deployment of funds set forth in the table below: (in ₹ million) Estimated amount Estimated schedule of proposed to be utilised deployment of Net Proceeds Particulars from Net Proceeds in Fiscal 2027 Repayment/ prepayment, in full or in part, of certain outstanding 5,098.51 5,098.51 borrowings, interest accrued and prepayment penalties, as applicable,

availed by: a. Our wholly-owned Subsidiaries, namely, Translumina 938.74 938.74 Therapeutics and Transhealth b. Our step-down Subsidiaries, namely, CPC Diagnostics Private 4,159.77 4,159.77 Limited, Chemopharm Sdn. Bhd.. and Research Instruments Pte.

Ltd.

General corporate purposes(1)(2) [●] [●] Total(2) [●] [●]

(1)The amount to be utilised for general corporate purposes shall not exceed 25% of the Gross Proceeds.

(2)To be finalized upon determination of the Offer Price and Offer Expenses and shall be updated in the Prospectus prior to filing with the RoC.

Pursuant to a resolution passed by the Board dated October 19, 2026, our Company has approved the utilisation of the Net Proceeds for the Object and the schedule of deployment and implementation, as set out above.

The above fund requirements are based on our current business plans, market trends, prevailing interest rates, management estimates and other external commercial and technical factors which are subject to change in the future. These are based on current conditions and are subject to revisions due to changes in costs, our financial condition, our business operations, growth strategies or external circumstances which may not be in our control, including evolutions in market trends.

Our fund requirements described herein have not been appraised by any bank or financial institution or other independent agency. For further details, please see “Risk Factors – Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior Shareholders’ approval. Further, our funding requirements and deployment of the Net Proceeds of the Offer are based on management estimates and have not been independently appraised. Our management will have broad discretion over the use of the Net Proceeds” on page [●]. However, the actual deployment of funds will depend on a number of factors, including the timing of completion of the Offer, market conditions, our Board’s analysis of economic trends and business requirements, ability to identify and consummate proposed investment and acquisition, competitive landscape, as well as general factors affecting our results of operations and financial condition.

This may entail rescheduling or revising the proposed utilization of the Net Proceeds, (including preponing the deployment of Net Proceeds), the implementation and deployment schedule provided above and our funding requirements, including the expenditure for a particular purpose, at the discretion of our management, subject to compliance with the applicable requirements under the Companies Act, the SEBI ICDR Regulations, the SEBI Listing Regulations and other applicable law.

In the event that the estimated utilization of the Net Proceeds in a scheduled Fiscal is not completely met, including due to the reasons stated above, the same shall be utilized in the next Fiscal as may be determined by our Company, in accordance with applicable laws.

We may have to revise our funding requirements and deployment on account of a variety of factors such as our financial and 7market condition, increase in the rate of taxation or change in the rate of currency exchange, our management’s analysis of economic trends and our business requirements, fund requirements in the operations of our Subsidiaries, inorganic and geographic expansion opportunities, our business and growth strategies, competitive landscape, general factors affecting our results of operations, financial condition and access to capital and other external factors such as changes in the business environment or regulatory climate and interest or exchange rate fluctuations, which may not be within the control of our management. This may entail revising the funding requirement for a particular Object or increasing or decreasing the amounts earmarked towards any of the aforementioned Objects at the discretion of our management, subject to compliance with applicable law.

In case of any surplus amount after utilization of the Net Proceeds towards the aforementioned Object, we may use such surplus amount towards general corporate purposes, subject to applicable laws to the extent that the total amount to be utilized towards general corporate purposes will not exceed 25% of the Gross Proceeds in accordance with the SEBI ICDR Regulations. Further, in case of a shortfall in meeting the aforementioned Objects, we may explore a range of alternate funding options including availing future debt from lenders. We believe that such alternate funding arrangements would be available to fund any such shortfalls.

For further information on factors that may affect our internal management estimates for the deployment of funds towards the Objects, see “Risk Factors - Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior Shareholders’ approval. Further, our funding requirements and deployment of the Net Proceeds of the Offer are based on management estimates and have not been independently appraised. Our management will have broad discretion over the use of the Net Proceeds” on page [●].

Means of finance The fund-requirements for the Objects are proposed to be met entirely from the Net Proceeds. Accordingly, our Company confirms that there is no requirement to make firm arrangements of finance through verifiable means towards at least 75% of the stated means of finance, excluding the amount to be raised through the Fresh Issue as required under Regulation 7(1)(e) the SEBI ICDR Regulations.

Details of the Objects Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by (a) wholly-owned Subsidiaries, namely, Translumina Therapeutics and Transhealth (b) step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd.

The following wholly-owned Subsidiaries have entered into various financial arrangements, including borrowings in the form of term loans, working capital facilities with banks and financial institutions:

1. Translumina Therapeutics, an Indian company (wholly owned by our Company)

2. Transhealth, an Indian company (wholly owned by our Company); and (for the purposes of this Object, collectively referred to as “Wholly Owned Subsidiaries”), Further, the following step-down Subsidiaries have entered into various financial arrangements, including borrowings in the form of term loans, working capital facilities with banks and financial institutions:

1. CPC Diagnostics Private Limited, an Indian company (64.61% held by Everlife Holdings Pte. Ltd. and 10.62 % held by our Company);

2. Chemopharm Sdn. Bhd., a Malaysian company (100% held by Everlife Holdings Pte. Ltd.); and

3. Research Instruments Pte. Ltd., a Singapore-based company (wholly-owned by Chemopharm Sdn. Bhd.) (for the purposes of this Object, collectively referred to as “Step-Down Subsidiaries”) As of August 31, 2026 we had total borrowings of ₹8,627.64 million on a consolidated basis. For further details, see “Financial Indebtedness” beginning on page [●].

Our Company proposes to utilise an estimated amount of ₹938.74 million and ₹4,159.77 million, respectively, aggregating to ₹5,098.51 million , from the Net Proceeds towards prepayment or repayment, in full or in part, of all or a portion of certain outstanding borrowings (including interest accrued and prepayment penalties as applicable), availed by our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries (such loans, “Identified Loans”), respectively, which constitutes 10.88% and

48.21%, respectively, of our total outstanding borrowings, on a consolidated basis, as of August 31, 2026. Pursuant to the terms of the borrowing arrangements entered into by Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, prepayment of certain indebtedness may attract prepayment charges as prescribed by the respective lender. Such prepayment charges, as applicable, and the accrued interest on our outstanding borrowings will also be funded out of the Net Proceeds. Our Company 8confirms that it will not utilize more than 50% of the proceeds of the Fresh Issue towards repayment/ prepayment of term loan facilities utilised towards capital expenditure.

Further, we intend to utilise the entire amount earmarked for this object in Fiscals 2027 in relation to repayment / prepayment the Identified Loans. In relation to our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, such deployment of Net Proceeds is being undertaken in Fiscals 2027 and will be subject to the timelines of infusion of funds by our Company in the Wholly-Owned Subsidiaries and our Step-down Subsidiaries and the subsequent repayment/ prepayment of outstanding borrowings by such Wholly-Owned Subsidiaries and Step-Down Subsidiaries, post infusion of such funds. For further details, see “- Proposed schedule of implementation and deployment of Net Proceeds” on page [●].

The repayment/ prepayment will help our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, reduce their respective outstanding indebtedness, assist us in reducing our interest outflow and enable utilisation of some additional amount from our internal accruals for further investment in business growth and expansion.

In addition, we believe that our debt-equity ratio will improve, which will enable us to raise additional funds/ capital at competitive rates in the future to fund potential business development opportunities and plans to grow and expand our business in the future. The following table set forth details of the Identified Loans availed by our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, as applicable, which are outstanding as on June 30, 2025 and August 31, 2026 which we will repay/ prepay, all or a portion of, from the Net Proceeds 9Utilisation of loans by our Wholly-Owned Subsidiaries, namely, Translumina Therapeutics and Transhealth Sr. Name of Name of the Date of Loan Nature of Amount Amount Amount Amount Tenor/ Repayment Interest rate Interest rate Purpose for Prepayment No. the lender borrower sanction letter disbursement borrowing sanctioned/ sanctioned/ outstanding outstanding schedule as at June 30, as at August which the loan clause (if / facility dates(s) availed as on availed as on as on June 30, as on 2026 (in %) 31, 2026 (in was availed(1) any) agreement June 30, 2026 August 31, 2026 (₹ in August 31, %)* and original (₹ in million) 2026 (₹ in million) 2026 (₹ in purpose of the million)* million)* loan (in case subsequent loans are for refinancing / reimbursement / takeover of existing loans, etc.

1. Citibank, Translumina Letter dated N.A.(2) C ash credit 600.00(1) 600.00* 491.90(1) 431.22* Maximum 12 Average Average Financing its Up to 2% per N.A.(1) Therapeutics January 2, months from the interest rate is interest rate is Working capital annum on the Private 2026^ date of the sanction 9.50%(1) 8.66%* r equirements prepaid Limited letter amount in case of loan prepayment (for the period computed as difference between the date of prepayment to the maturity date or next reset date whichever is earlier).

However, in respect of Facilities with floating rate interest, no such charges will be payable if a prepayment of such Facility is made on an Interest Reset Date

2. HDFC Translumina March 17, 2026 N.A .(2) Cash Credit 500.00(1) 505.50* 141.59(1) 116.87* Valid up to February Spread of 3% Interest Rate Business purpose Upto 4% of Bank(1) Therapeutics 02, 2027 with 3M Repo, Linked* for purchasing loan Principal Private i.e., 8.25(1) raw materials, outstanding 10Sr. Name of Name of the Date of Loan Nature of Amount Amount Amount Amount Tenor/ Repayment Interest rate Interest rate Purpose for Prepayment No. the lender borrower sanction letter disbursement borrowing sanctioned/ sanctioned/ outstanding outstanding schedule as at June 30, as at August which the loan clause (if / facility dates(s) availed as on availed as on as on June 30, as on 2026 (in %) 31, 2026 (in was availed(1) any) agreement June 30, 2026 August 31, 2026 (₹ in August 31, %)* and original (₹ in million) 2026 (₹ in million) 2026 (₹ in purpose of the million)* million)* loan (in case subsequent loans are for refinancing / reimbursement / takeover of existing loans, etc.

Limited N.A .(2) Buyer 260.63(1) 288.88* EURIBOR EURIBOR making payments for Term loan Credit Plus Spread Plus Spread to vendors and and 4% of the

1.7 % i.e. 1.7 % i.e. service payments sanctioned

4.10%(1) 4.42%* amount for Working Capital Facility (plus taxes).

Micro and Small Enterprises, as per BCSBI guidelines, prepayment charges will not be levied if the said borrower is prepaying the floating rate loans and for fixed rates loans upto a cap of 50 lakhs to reduce the business liabilities.

Bank reserves the right to enquire or ask the documentary proof Of source of funds for closure request of loans.

11Sr. Name of Name of the Date of Loan Nature of Amount Amount Amount Amount Tenor/ Repayment Interest rate Interest rate Purpose for Prepayment No. the lender borrower sanction letter disbursement borrowing sanctioned/ sanctioned/ outstanding outstanding schedule as at June 30, as at August which the loan clause (if / facility dates(s) availed as on availed as on as on June 30, as on 2026 (in %) 31, 2026 (in was availed(1) any) agreement June 30, 2026 August 31, 2026 (₹ in August 31, %)* and original (₹ in million) 2026 (₹ in million) 2026 (₹ in purpose of the million)* million)* loan (in case subsequent loans are for refinancing / reimbursement / takeover of existing loans, etc.

3. ICICI Translumina January 24, N.A.(2) Cash Credit 100.00(1) 100.00* 61.36(1) 82.54* Valid up to Interest rate is Working capital - Bank(1) Therapeutics 2025 read with December 22, 2026 repo rate of Interest rate is facilities Private the letter dated 5.25% and repo rate of Limited January 9, spread of 3.6% 5.25% and 2026 i .e. 8.85%(1) spread of 3.6% i.e. 8.85%*

4. ICICI Transhealth January 28, N.A.(2) Cash Credit 20.20(1) 20.20* 13.70(1) 17.99* Valid up to January 8.55%(1) 8.55%* Working capital - Bank(1) Private 2025, read 11, 2027 facilities Limited with the letter dated January 13, 2026

5. Citibank Transhealth April 3, 2025, N.A .(2) Cash credit 150.00(1) 150.00* 127.56(1) 134.11* 12 months from date 9.17%(1) 8.66%* Working capital Up to 2% per N.A.(1) Private read with the of sanction letter facilities and annum on the Limited letter dated capital prepaid January 5, expenditure amount in 2026$ case of loan prepayment (for the period computed as difference between the date of prepayment to the maturity date or next reset date whichever is earlier).

However, in respect of Facilities with floating rate interest, no such charges will be payable if a prepayment of such Facility is made on an 12Sr. Name of Name of the Date of Loan Nature of Amount Amount Amount Amount Tenor/ Repayment Interest rate Interest rate Purpose for Prepayment No. the lender borrower sanction letter disbursement borrowing sanctioned/ sanctioned/ outstanding outstanding schedule as at June 30, as at August which the loan clause (if / facility dates(s) availed as on availed as on as on June 30, as on 2026 (in %) 31, 2026 (in was availed(1) any) agreement June 30, 2026 August 31, 2026 (₹ in August 31, %)* and original (₹ in million) 2026 (₹ in million) 2026 (₹ in purpose of the million)* million)* loan (in case subsequent loans are for refinancing / reimbursement / takeover of existing loans, etc.

Interest Reset Date.

6. Citi Bank Transhealth April 3, 2025, January 15, Term Loan 93.40(1) 93.40* 55.41(1) 52.88* Repayable on 7.35%- 3.65%- Working capital Up to 2% per N.A.(1) Private read with the 2024, February different monthly 8.61%(1) 8.61%* facilities and annum on the Limited letter dated 26, 2024, tenors capital prepaid January 5, 2026 June 18, 2024 expenditure amount in (acquisition of case of loan machine)^^ prepayment (for the period Original computed as

purpose: working difference capital between the date of prepayment to the maturity date or next reset date whichever is earlier).

However, in respect of Facilities with floating rate interest, no such charges will be payable if a prepayment of such Facility is made on an Interest Reset Date.

Total 1,463.60 1,463.60 1,152.15 1,124.49 * Details as at August 31, 2026 are as certified by J.C. Bhalla & Co., Chartered Accountants (FRN: 001111N), by way of their certificate dated [●] (UDIN:[●]). Totals include amounts certified by Walker Chandiok & Co LLP and J.C.

Bhalla & Co., as indicated against each line item. ** This facility has been renewed. ^ This facility has been renewed.

13^^The sanction letter refers the purpose of the loan as both working capital and capital expenditure. However, for assessment purposes, the entire loan has been treated as having been utilized solely for capital expenditure.

$ This facility has been renewed.

(1) In accordance with Clause 9(A)(2)(b) of Part A of Schedule VI of the SEBI ICDR Regulations which requires a certificate from the statutory auditor certifying the utilization of loan for the purpose availed, our Company has obtained the requisite report dated [●] (UDIN:[●]) from Walker Chandiok & Co LLP (FRN: 001076N/N500013), our statutory auditors, in respect of details as at June 30, 2026 of loans availed by Translumina Therapeutics Private Limited and Transhealth Private Limited, as marked (1) above.

(2) Since these are working capital facilities, please note that there are no specific disbursal dates available for such facilities .

14Utilisation of loans by our Step-Down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd.

Sr. Name of Name of the Date of Loan Nature of Amount Amount Amount Amount Tenor/ Interest rate as at Interest rate as at Purpose for which the loan Prepayment No. the borrower sanction disbursemen borrowin sanctioned/ sanctioned/ outstandin outstandin Repaymen June 30, 2026 (in %) August 31, 2026 was availed(1) and original clause (if any) lender letter / t date(s) g availed as on availed as on g as on g as on t schedule (in %)* purpose of the loan (in case facility June 30, 2026 August 31, June 30, August 31, subsequent loans are for agreemen (₹ in million) 2026 (₹ in 2026 (₹ in 2026 (₹ in refinancing/ reimbursement t million)* million) million)* /takeover of existing loans, etc

1. Citi Bank CPC June 12, N.A.(3) Working Sanction Sanction 306.61(1) 384.42(2) Cash i) Averag i) i)Financing working capital Up to 2% per N.A.(1) Diagnostics 2026 Capital limits:(1) limits:(2) credit: 12 e interest rate for Average interest requirements annum on the Private facilities months cash credit is 9.00 % rate is 9.00 % p.a(2) prepaid amount Limited a. Cash Overall Overall from date of ii) ii)Issuing bank guarantee to in case of loan p.a(1) Credit Sanction limit- Sanction limit- utilisation Average interest customers prepayment b. ₹ 493.50 ₹ 493.50 ii) Averag rate is 6.71 % p.a(2) (for the period

Working million million Working e interest rate for Original purpose: computed as

capital includes: includes: capital trade pay is 6.75 % Financing working capital difference

demand loans: 6 p.a(1) requirements between the Loan Working Working months date of c. Non Capital - ₹ Capital - ₹ from the prepayment to fund based 475.00 Million 475.00 Million date of the maturity date - Bank utilisation or next reset Guarantee, i) Cash credit i) Cash credit date whichever Usance of and working and working Non-fund is earlier).

Letter of capital demand capital demand based: Average interest rate Average interest However, in credit, loan - loan - Maximum is 6.90% p.a rate is 6.90% p.a respect of Buyers ₹475.00million ₹475.00millio tenor of Facilities with credit, n seven years floating rate Sight letter ii) Non- fund from the interest, no o f credit based limit ii) Non- fund date of such charges (sub-limit) - based limit utilisation will be ₹150.00million (sub-limit) - payable if a ₹150.00millio prepayment of n such Facility is made on an Interest Reset Date

2. Citi Bank CPC June 12, April 13, Term 18.50(1) 18.50(2) 18.00(1) 13.50(2) 5 years 9.07%(1) 9.09%(2) Reimbursement of capital Prepayment N.A.(1) Diagnostics 2026 2022 Loan with 20 expenditure incurred in Fiscal penalty at the Private equal 2021 and Fiscal 2022 which rate of 2% of Limited quarterly was availed for purchasing principal instalments instruments placed at outstanding, at laboratories and hospitals the discretion of Citibank N.A.

15Sr. Name of Name of the Date of Loan Nature of Amount Amount Amount Amount Tenor/ Interest rate as at Interest rate as at Purpose for which the loan Prepayment No. the borrower sanction disbursemen borrowin sanctioned/ sanctioned/ outstandin outstandin Repaymen June 30, 2026 (in %) August 31, 2026 was availed(1) and original clause (if any) lender letter / t date(s) g availed as on availed as on g as on g as on t schedule (in %)* purpose of the loan (in case facility June 30, 2026 August 31, June 30, August 31, subsequent loans are for agreemen (₹ in million) 2026 (₹ in 2026 (₹ in 2026 (₹ in refinancing/ reimbursement t million)* million) million)* /takeover of existing loans, etc

3. HSBC CPC March 6, N.A.(3) Cash Combined Combined 63.92(1) 31.01(2) Working Average interest rate Average interest Financing working capital Any prepayment Bank(1) Diagnostics 2025, read credit Limit:(1) Limit:(2) Capital for cash credit is 7.39 rate for cash credit requirements. will be subject Private with letter ₹200.00millio ₹200.00 Loan:(120 % p.a. (1) is 7.32 % p.a. (2) to HSBC Limited dated n million days + 1- Bank’s February Working Working day Average interest rate Average interest discretion.

23, 2026 Capital Capital cooling) for tradepay is 6.85% rate for tradepay is

Loan:(1) Loan:(2) p.a.(1) 6.85% p.a.(2) ₹200.00(120 ₹200.00(120 Overdraft: days + 1-day days + 1-day On cooling) cooling) Demand TradePay

(Import):(2) Others: 120 TradePay ₹200.00 days

(Import):(1) million or ₹200.00 FCY Further, million or FCY equivalent next equivalent (120 days) renewal of (120 days) the facility is due on November 30,2026 N.A.(3) Import/ 90.77(1) 114.94(2) Maximum To finance import/domestic Buyer 120 days payables of the borrower for

Facility: from the the purposes of payment to TradePay date of suppliers for import of

(Import) utilisation. instruments and reagents

4. HSBC Chemophar October November Term 1,981.13(1) 2,000.00(2) 1,827.36(1) 1,943.82(2) Repayment Margin + Reference Margin + A. Financing the direct Illegality Bank(1) m Sdn. Bhd. 28, 2024 11,, 2024 Loan at different rate(1) Reference rate(2) repayment or prepayment of If, at any time, it is (US$) intervals As per sanction As per sanction the Existing Financial or will become from date letter, Margin- letter, Margin- Indebtedness by the Borrower unlawful in any of 2.20% p.a 2.20% p.a and/or the direct repayment or applicable utilisation, Reference rate - the Reference rate - prepayment by the Borrower jurisdiction for i.e., 12, 18, applicable Primary the applicable of an intercompany loan a Lender to 24, 30, 36, Term Rate for the Primary Term Rate between the Borrower and perform any of 42 or 48 applicable currency for the applicable Chemoinformatics Sdn Bhd, its obligations months of a Loan as of the currency of a Loan the proceeds of which are used as with quotation Time for a as of the quotation contemporaneously by contemplated different period equal in Time for a period Chemoinformatics Sdn Bhd by this applicable length to the Interest equal in length to for the repayment or Agreement or interest Period of that Loan. the Interest Period prepayment of the Existing to fund or rates. of that Loan. Financial Indebtedness;+ maintain its However, participation in the B. Financing the payment by any Loan or it maximum the Group of deferred is or will tenor consideration related to become available acquisition of Thai Material unlawful for shall not Entity 1;+ and any Affiliate of exceed 60 a Lender for months. C.The payment of fees, costs that Lender to 16Sr. Name of Name of the Date of Loan Nature of Amount Amount Amount Amount Tenor/ Interest rate as at Interest rate as at Purpose for which the loan Prepayment No. the borrower sanction disbursemen borrowin sanctioned/ sanctioned/ outstandin outstandin Repaymen June 30, 2026 (in %) August 31, 2026 was availed(1) and original clause (if any) lender letter / t date(s) g availed as on availed as on g as on g as on t schedule (in %)* purpose of the loan (in case facility June 30, 2026 August 31, June 30, August 31, subsequent loans are for agreemen (₹ in million) 2026 (₹ in 2026 (₹ in 2026 (₹ in refinancing/ reimbursement t million)* million) million)* /takeover of existing loans, etc

and expenses incurred and do so: payable by the Borrower under (a) that Lender the Finance Documents shall promptly

5. HSBC Chemophar October November Term 2,897.41(1) 2,963.12(2) 2,730.02(1) 2,814.96(2) Margin + Reference Margin + A. Financing the direct notify the Bank(1) m Sdn. Bhd. 28, 2024 11, 2024 Loan rate(1) Reference rate(2) repayment or prepayment of Agent upon

(MYR) As per sanction As per sanction the Existing Financial becoming letter, Margin- letter, Margin- Indebtedness by the Borrower aware of that

2.20% p.a 2.20% p.a and/or the direct repayment or event;

Reference rate - the Reference rate - prepayment by the Borrower (b) upon the applicable Primary the applicable of an intercompany loan Agent Term Rate for the Primary Term Rate between the Borrower and notifying the applicable currency for the applicable Chemoinformatics Sdn Bhd, Borrower, each of a Loan as of the currency of a Loan the proceeds of which are used Available quotation Time for a as of the quotation contemporaneously by Commitment period equal in Time for a period Chemoinformatics Sdn Bhd of that Lender length to the Interest equal in length to for the repayment or will be Period of that Loan. the Interest Period prepayment of the Existing immediately of that Loan. Financial Indebtedness; cancelled; and

(c) to the extent B. Financing the payment by that the the Group of deferred Lender's consideration related to participation acquisition of Thai Material has not been Entity 1; and transferred pursuant to C.The payment of fees, costs Clause 35.6 and expenses incurred and (Replacement payable by the Borrower under of Lender), the the Finance Documents Borrower shall repay that Lender's participation in the Utilizations made to the Borrower on the earliest of the following

dates:

(i) the last day of the Interest Period for each Loan occurring immediately after the Agent has notified the Borrower; and

(ii) the date specified by that Lender in the notice 17Sr. Name of Name of the Date of Loan Nature of Amount Amount Amount Amount Tenor/ Interest rate as at Interest rate as at Purpose for which the loan Prepayment No. the borrower sanction disbursemen borrowin sanctioned/ sanctioned/ outstandin outstandin Repaymen June 30, 2026 (in %) August 31, 2026 was availed(1) and original clause (if any) lender letter / t date(s) g availed as on availed as on g as on g as on t schedule (in %)* purpose of the loan (in case facility June 30, 2026 August 31, June 30, August 31, subsequent loans are for agreemen (₹ in million) 2026 (₹ in 2026 (₹ in 2026 (₹ in refinancing/ reimbursement t million)* million) million)* /takeover of existing loans, etc delivered to the Borrower (being no earlier than the last day of any applicable grace period permitted by law), and that Lender's corresponding Commitment(s ) shall be cancelled in the amount of the participation repaid.

Mandatory prepayment - Flotation or Change of Control

(a) Upon the

occurrence of:

(1) a Change of Control;

(ii) a Flotation that is not an Approved Flotation;

(iii) the sale of all or substantially all of the assets of the Group whether in a single transaction or a series of related transactions, the Obligors' Agent shall promptly notify the Agent upon becoming aware of that

event and:

(A) no Lender shall not be obliged to fund 18Sr. Name of Name of the Date of Loan Nature of Amount Amount Amount Amount Tenor/ Interest rate as at Interest rate as at Purpose for which the loan Prepayment No. the borrower sanction disbursemen borrowin sanctioned/ sanctioned/ outstandin outstandin Repaymen June 30, 2026 (in %) August 31, 2026 was availed(1) and original clause (if any) lender letter / t date(s) g availed as on availed as on g as on g as on t schedule (in %)* purpose of the loan (in case facility June 30, 2026 August 31, June 30, August 31, subsequent loans are for agreemen (₹ in million) 2026 (₹ in 2026 (₹ in 2026 (₹ in refinancing/ reimbursement t million)* million) million)* /takeover of existing loans, etc a Utilisation;

and

(B) the Total Commitments will be cancelled and all outstanding Loans, together with accrued interest and all other amounts accrued under the Finance Documents will become immediately due and payable by the Borrower.

6. Malayan Chemophar December N.A.(3) Multiple 254.97(1) 215.31(2) 153.12(1) 162.71(2) Repayable FEC: Forex Rate(1) FEC: Forex Rate(2) Foreign Exchange contract One (1) month’s Banking m Sdn. Bhd. 13, 2023, bank on demand LC: Commission at LC: Commission limit (FECL): To hedge prior written Berhad(1) read with facility 0.10% per month at 0.10% per against foreign exchange notice or by letter (Minimum month (Minimum fluctuation for foreign paying one (1) dated RM75.00) RM75.00) purchases/sales made during month’s

November TR: Base Lending TR: Base Lending normal trade transactions. interest in lieu 27, 2025 Rate (BLR) + 1.25% Rate (BLR) + of notice. per annum 1.25% per annum Letter of Credit (LC) - BA: 1.25% BA: 1.25% Sight/Usance: 120 days acceptance acceptance Trust Receipt (TR) Tenor: 120 commission commission days Invoice Financing Invoice Financing Banker's Acceptance (BA)-For

(IF) for Goods: Cost (IF) for Goods: Purchase/Imports-Tenor: 120 of Fund (COF) + Cost of Fund days

1.25% per annum, (COF) + 1.25% per Invoice Financing (IF) for based on selected annum, based on Goods-For Purchase/Imports- currencies. selected Tenor: 120 days Repricing not currencies. Invoice Financing (IF) for allowed Repricing not Services -Tenor: 120 days Invoice Financing allowed Bank Guarantee (BG) -

(IF) for Services: Invoice Financing Financial/Non-Financial COF + 1.25% per (IF) for Services: Standby Letter of Credit annum, based on COF + 1.25% per (SBLC) selected currencies. annum, based on Onshore Foreign Currency Repricing not selected Loan (OFCL)-For Imports- allowed currencies. Tenor: 120 days BG: Commission at Repricing not

0.10% per month allowed Original purpose: working (Minimum BG: Commission capital 19Sr. Name of Name of the Date of Loan Nature of Amount Amount Amount Amount Tenor/ Interest rate as at Interest rate as at Purpose for which the loan Prepayment No. the borrower sanction disbursemen borrowin sanctioned/ sanctioned/ outstandin outstandin Repaymen June 30, 2026 (in %) August 31, 2026 was availed(1) and original clause (if any) lender letter / t date(s) g availed as on availed as on g as on g as on t schedule (in %)* purpose of the loan (in case facility June 30, 2026 August 31, June 30, August 31, subsequent loans are for agreemen (₹ in million) 2026 (₹ in 2026 (₹ in 2026 (₹ in refinancing/ reimbursement t million)* million) million)* /takeover of existing loans, etc RM100.00) at 0.10% per

SBLC: Commission month (Minimum at 0.10% per month RM100.00) (Minimum SBLC:

RM100.00) Commission at

OFCL: COF + 0.10% per month

1.25% per annum, (Minimum based on selected RM100.00)

foreign currencies OFCL: COF +

1.25% per annum, based on selected foreign currencies

7. CIMB Chemophar July 22, N.A.(3) Multiple 162.26(1) 165.93(2) 123.27(1) 161.45(2) FELC/ BG/ OD-Bank Base rate OD-Bank Base Foreign Exchange contract No prepayment of Bank(1) m Sdn Bhd 2024 bank OD: +1.25%(1) rate +1.25%(2) limit (FECL): To hedge the Facilities facility Repayable DC- 0.10%per DC- 0.10%per against foreign exchange may be on demand month month fluctuation for foreign available for TR-Bank Base rate TR-Bank Base rate purchases/sales made during redrawing or be BA/ DC/ +1.25% +1.25% normal trade transactions. reborrowed TR: Upon BA-1% per annum BA-1% per annum Overdraft (OD): For working unless agreed maturity of BG-0.15% per BG-0.15% per capital requirements. upon by the the tenor month month Bank guarantee (BG): For Bank in writing and/or FECL-Prevailing FECL-Prevailing tender, performance and repayable Foreign exchange Foreign exchange deposits to on demand, rate rate utilities/customs/immigrations whichever .

is earlier Banker Acceptance (BA): To finance purchases/imports of trade-related goods.

Documentary credit (DC): To facilitate importation and purchase of goods.

Trust receipt (TR): To finance goods under DC and Inwards Bills of Collection

Original purpose: working capital

8. Standard Chemophar June 4, N.A.(3) Multiple 324.51(1) 331.87(2) 278.18(1) 300.88(2) Maximum 1.20% p.a. over the 1.20% p.a. over the Letters of Credit (""LC"") - Chartere m Sdn Bhd 2025** bank tenure of cost of the funds(1) cost of the funds(2) Secured/Unsecured-Drafts d Bank(1) facility 150 days and/or documents payable at from the sight or usance date of Import Loan-Import Loans utilisation. covering the release of goods imported by the Borrower under and in relation to Letters of Credit issued or import bills for collection handled by the Bank.

Invoice financing-For 20Sr. Name of Name of the Date of Loan Nature of Amount Amount Amount Amount Tenor/ Interest rate as at Interest rate as at Purpose for which the loan Prepayment No. the borrower sanction disbursemen borrowin sanctioned/ sanctioned/ outstandin outstandin Repaymen June 30, 2026 (in %) August 31, 2026 was availed(1) and original clause (if any) lender letter / t date(s) g availed as on availed as on g as on g as on t schedule (in %)* purpose of the loan (in case facility June 30, 2026 August 31, June 30, August 31, subsequent loans are for agreemen (₹ in million) 2026 (₹ in 2026 (₹ in 2026 (₹ in refinancing/ reimbursement t million)* million) million)* /takeover of existing loans, etc financing goods purchased by the Borrower from its seller, as evidenced by the seller's invoice to the Borrower.

Original purpose: Funding working capital requirements

9. HSBC Research November N.A. Trust 343.37 352.35 137.23 217.04 The SOFR (Secured SOFR (Secured Working Capital Requirement - Bank(4) Instruments 5, 2024 Receipts Subsidiary Overnight Financing Overnight Pte. Ltd. Company Rate) Term Rate + Financing Rate) has availed Margin 2%, as Term Rate + Loan conclusively Margin 2%, as against determined by the conclusively import bank from time to determined by the with Trust time*BRL + 2% p.a. bank from time to Receipt at over the bank's cost time*BRL + 2% the rate of of funds, as p.a. over the bank's SOFR conclusively cost of funds, as (Secured determined by the conclusively Overnight bank from time to determined by the Financing time bank from time to Rate) Term time Rate + Margin 2%.

Maximum loan period of 150 days.

Total 6,675.65 6,740.58 5,728.48 6,144.73 % The outstanding amount is more than the sanctioned amount due to fluctuations in exchange rates. +Chemopharm Sdn. Bhd. (“Chemopharm”) had availed a term loan (in USD) (“Main Loan 1”) and term loan (in MYR) (“Main Loan 2”) from HSBC Bank (“Lender”) pursuant to sanction letters each dated October 28, 2024 (Main Loan 1 and Main Loan 2 collectively referred to as “Main Loans”), which we propose to repay/prepay (in full or in part) from the Net Proceeds. Prior to this, Chemoinformatics Sdn. Bhd. (“Chemoinformatics”) had availed a loan from Standard Chartered Bank and Malayan Banking Berhad (collectively, “Original Lenders”) pursuant to the facilities agreement dated June 7, 2022, read with the amended and restated agreement dated January 30, 2024 for an amount of MYR 65,000,000 (“Original Loan” and such amount, the “Original Loan Amount”). The purpose of the Original Loan was to facilitate the acquisition of Hausen Bernstein Company Limited by Chemopharm. To facilitate this, Chemoinformatics had lent the Original Loan Amount to Chemopharm through an inter-company loan (“Inter-Company Loan”), such that Chemopharm could acquire the shares of Hausen Bernstein Company Limited. Accordingly, Chemopharm utilised the Inter-Company Loan for the purposes of acquiring Hausen Bernstein Company Limited. Thereafter, Chemopharm availed the abovementioned Main Loans to, among others, refinance the Inter-Company Loan and repay Chemoinformatics, which was thereafter used by Chemoinformatics to repay the Original Loan Amount. As on August 31, 2026 the amount sanctioned under Main Loan 1 was ₹ 2,000.00 million and the amount sanctioned under Main Loan 2 was ₹ 2,963.12 million. Further, as on August 31, 2026, the amount outstanding under Main Loan 1 was ₹ 1,943.82 million and the amount outstanding under Main Loan 2 was ₹ 2,814.96 million. Set forth below is a pictorial diagram of the Main Loans vis-à-vis the Original Loan and the Inter-Company Loan:

21(1) In accordance with Clause 9(A)(2)(b) of Part A of Schedule VI of the SEBI ICDR Regulations which requires a certificate from the statutory auditor certifying the utilization of loan for the purpose availed, our Company has obtained the requisite report dated [●] (UDIN:[●]) from Walker Chandiok & Co LLP (FRN: 001076N/N500013), our statutory auditors, in respect of details as at June 30, 2026 of loans availed by CPC Diagnostics Private Limited and Chemopharm Sdn. Bhd., as marked (1) above.

(2) In accordance with Clause 9(A)(2)(b) of Part A of Schedule VI of the SEBI ICDR Regulations which requires a certificate from the statutory auditor/independent chartered accountant certifying the utilization of loan as at August 31, 2026, as marked (2) above, have been certified by way of certificate dated [●] (UDIN:[●]) from J.C. Bhalla & Co, Chartered Accountants (FRN: 001111N).

(3) Since these are working capital facilities, please note that there are no specific disbursal dates available for such facilities.

(4) The details of loan availed by Research Instruments Pte. Ltd., as marked (4) above, including as at June 30, 2026 and utilisation thereof, have been certified by J.C. Bhalla & Co, Chartered Accountants (FRN: 001111N) by their certificate dated [●].

Note:

Sanctioned Amount relates to foreign currency loans that has been translated at closing exchange as on reporting date. The Outstanding balances as at June 30, 2026 of respective facility is taken as per books of accounts, while the balances as at August 31, 2026 is balances as per bank statements. Totals include amounts certified by Walker Chandiok & Co LLP and J.C. Bhalla & Co., as indicated as (1), (2) or (4) against each line item.

22The following table bifurcates between the purpose of the Identified Loans availed by our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, as applicable, i.e., whether the Identified Loans were availed for the purposes of capital expenditure or for purposes other than capital expenditure I. Identified Loans availed for the purposes of capital expenditure The following table set forth details of the Identified Loans availed for the purposes of capital expenditure by our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, as applicable, which are outstanding as on June 30, 2026 and August 31, 2026, which we may repay/ prepay, all or a portion of, from the Net Proceeds.

Sr. Name Name of the Date of Nature of Amount outstanding Amount Purpose for which No. of the borrower sanction borrowing as on June 30, 2026 outstanding as on the loan was lender letter / (₹ in million) August 31, 2026 (₹ availed(1) facility in million)* agreement Wholly-Owned Subsidiaries

1. Citi Transhealth April 3, Term Loan 55.41 52.88 Working capital Bank Private 2025, read facilities and capital N.A.(1) Limited with the letter expenditure dated January (acquisition of 5, 2026$ machine)^ Step-Down Subsidiaries

2. Citi CPC June 12, 2026 Term Loan 18.00 13.50 Reimbursement of Bank Diagnostics capital expenditure N.A.(1) Private incurred in Fiscal Limited 2021 and Fiscal 2022 which was availed for purchasing instruments placed at laboratories and hospitals

3. HSBC Chemopharm October 28, Term Loan 1,849.28 1,943.82 A. Financing the Bank Sdn. Bhd. 2024 direct repayment or

(1) prepayment of the Existing Financial Indebtedness by the Borrower and/or the direct repayment or prepayment by the Borrower of an intercompany loan between the Borrower and Chemoinformatics Sdn. Bhd., the proceeds of which are used contemporaneously by Chemoinformatics Sdn. Bhd. for the repayment or prepayment of the Existing Financial Indebtedness;+ B. Financing the payment by the Group of deferred consideration related to acquisition of Thai Material Entity 23Sr. Name Name of the Date of Nature of Amount outstanding Amount Purpose for which No. of the borrower sanction borrowing as on June 30, 2026 outstanding as on the loan was lender letter / (₹ in million) August 31, 2026 (₹ availed(1) facility in million)* agreement 1;+ and C. The payment of fees, costs and expenses incurred and payable by the Borrower under the Finance Documents

4. HSBC Chemopharm October 28, Term Loan 2,714.67 2,814.96 A. Financing the Bank(1) Sdn. Bhd. 2024 direct repayment or prepayment of the Existing Financial Indebtedness by the Borrower and/or the direct repayment or prepayment by the Borrower of an intercompany loan between the Borrower and Chemoinformatics Sdn. Bhd., the proceeds of which are used contemporaneously by Chemoinformatics Sdn. Bhd. for the repayment or prepayment of the Existing Financial Indebtedness;

B. Financing the payment by the Group of deferred consideration related to acquisition of Thai Material Entity 1; and C. The payment of fees, costs and expenses incurred and payable by the Borrower under the Finance Documents Total 4,637.36 4,825.16 * As certified by J.C. Bhalla & Co., Chartered Accountants (FRN: 001111N), by way of their certificate dated [●] [●] (UDIN:[●]).

** This facility has been renewed. % The outstanding amount is more than the sanctioned amount due to fluctuations in exchange rates. ^ The sanction letter refers the purpose of the loan as both working capital and capital expenditure. However, for assessment purposes, the entire loan has been treated as having been utilized solely for capital expenditure.

+ Chemopharm Sdn. Bhd. (“Chemopharm”) had availed a term loan (in USD) (“Main Loan 1”) and term loan (in MYR) (“Main Loan 2”) from HSBC Bank (“Lender”) pursuant to sanction letters each dated October 28, 2024 (Main Loan 1 and Main Loan 2 collectively referred to as “Main Loans”), which we propose to repay/prepay (in full or in part) from the Net Proceeds. Prior to this, Chemoinformatics Sdn. Bhd.

(“Chemoinformatics”) had availed a loan from Standard Chartered Bank and Malayan Banking Berhad (collectively, “Original Lenders”) pursuant to the facilities agreement dated June 7, 2022, read with the amended and restated agreement dated January 30, 2024 for an amount of MYR 65,000,000 (“Original Loan” and such amount, the “Original Loan Amount”). The purpose of the Original Loan was to facilitate the acquisition of Hausen Bernstein Company Limited by Chemopharm. To facilitate this, Chemoinformatics had lent the Original Loan Amount to Chemopharm through an inter-company loan (“Inter-Company Loan”), such that Chemopharm could acquire the shares of Hausen Bernstein Company Limited. Accordingly, Chemopharm utilised the Inter-Company Loan for the purposes of acquiring Hausen Bernstein Company Limited. Thereafter, Chemopharm availed the abovementioned Main Loans to, among others, refinance the Inter- Company Loan and repay Chemoinformatics, which was thereafter used by Chemoinformatics to repay the Original Loan Amount. As on August 31, 2026 the amount sanctioned under Main Loan 1 was ₹ 2,000.00 million and the amount sanctioned under Main Loan 2 was ₹ 242,963.12 million. Further, as on August 31, 2026, the amount outstanding under Main Loan 1 was ₹ 1,943.82 million and the amount outstanding under Main Loan 2 was ₹ 2,814.96 million. Set forth below is a pictorial diagram of the Main Loans vis-à-vis the Original Loan and the Inter-Company Loan:

(1) In accordance with Clause 9(A)(2)(b) of Part A of Schedule VI of the SEBI ICDR Regulations which requires a certificate from the statutory auditor certifying the utilization of loan for the purpose availed, our Company has obtained the requisite report dated [●] (UDIN:[●]) from Walker Chandiok & Co LLP (FRN: 001076N/N500013), our statutory auditors.

II. Identified Loans availed for purposes other than capital expenditure The following table set forth details of the Identified Loans availed for purposes other than capital expenditure by our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries, as applicable, which are outstanding as on June 30, 2026 and August 31, 2026, as applicable, which we may repay/ prepay, all or a portion of, from the Net Proceeds.

Sr. Name of Name of the Date of sanction Nature of Amount Amount Purpose for which the loan No. the borrower letter / facility borrowing outstanding outstanding was availed(1) lender agreement as on June as on 30, 2026 (₹ August 31, in million) 2026 (₹ in million) Wholly-Owned Subsidiaries

1. Citibank, Translumina January 2, 2026 Cash credit 491.90 431.22 Financing its Working capital N.A. Therapeutics requirements Private Limited

2. HDFC Translumina March 17, 2026** Cash 141.59 116.87 Business purpose for Bank Therapeutics Credit purchasing raw materials, Private Buyer 260.63 288.88 making payments to vendors Limited Credit and service payments

3. ICICI Translumina January 9, 2026 Cash 61.36 82.54 Working capital facilities Bank Therapeutics Credit Private Limited

4. ICICI Transhealth January 13, 2026 Cash 13.70 17.99 Working capital facilities Bank Private Credit Limited 25Sr. Name of Name of the Date of sanction Nature of Amount Amount Purpose for which the loan No. the borrower letter / facility borrowing outstanding outstanding was availed(1) lender agreement as on June as on 30, 2026 (₹ August 31, in million) 2026 (₹ in million)

5. Citibank Transhealth January 5, 2026 Cash credit 134.11 Working capital facilities N.A. Private 127.56 - Limited Step-Down Subsidiaries

1. Citi Bank CPC June 12, 2026** Working 306.61 384.42 i)Financing working capital N.A. Diagnostics Capital requirements Private facilities Limited a. Cash ii) Issuing bank guarantee to Credit customers b. Working capital demand Loan c. Non fund based - Bank Guarantee, Usance of Letter of credit, Buyers credit, Sight letter of credit d. Term Loan

2. HSBC CPC February 23, 2026 Cash 63.92 31.01 Financing working capital Bank Diagnostics credit requirements.

Private Limited Import/ 90.77 114.94 To finance import/domestic Buyer payables of the borrower for the

Facility: purposes of payment to suppliers TradePay for import of instruments and

(Import) reagents

3. Malayan Chemopharm November 27, 2025 Multiple 153.12 162.71 Foreign Exchange contract Banking Sdn. Bhd. bank limit (FECL): To hedge against Berhad facility foreign exchange fluctuation for foreign purchases/sales made during normal trade transactions.

Letter of Credit (LC) - Sight/Usance: 120 days Trust Receipt (TR) Tenor: 120 days Banker's Acceptance (BA)-For Purchase/Imports-Tenor: 120 days Invoice Financing (IF) for Goods-For Purchase/Imports-

Tenor: 120 days Invoice Financing (IF) for Services -Tenor: 120 days Bank Guarantee (BG) - Financial/Non-Financial Standby Letter of Credit

(SBLC) Onshore Foreign Currency 26Sr. Name of Name of the Date of sanction Nature of Amount Amount Purpose for which the loan No. the borrower letter / facility borrowing outstanding outstanding was availed(1) lender agreement as on June as on 30, 2026 (₹ August 31, in million) 2026 (₹ in million) Loan (OFCL)-For Imports-

Tenor: 120 days

4. CIMB Chemopharm July 22, 2024 Multiple 123.27 161.45 Foreign Exchange contract Bank Sdn. Bhd. bank limit (FECL): To hedge against facility foreign exchange fluctuation for foreign purchases/sales made during normal trade transactions.

Overdraft (OD): For working capital requirements.

Bank guarantee (BG): For tender, performance and deposits to utilities/customs/immigrations.

Banker Acceptance (BA): To finance purchases/imports of trade-related goods.

Documentary credit (DC): To facilitate importation and purchase of goods.

Trust receipt (TR): To finance goods under DC and Inwards Bills of Collection

5. Standard Chemopharm June 4, 2025** Multiple 278.18 300.88 Letters of Credit (""LC"") Chartered Sdn. Bhd. bank Secured/Unsecured-Drafts Bank facility and/or documents payable at sight or usance Import Loan-Import Loans covering the release of goods imported by the Borrower under and in relation to Letters of Credit issued or import bills for collection handled by the Bank.

Invoice financing-For financing goods purchased by the Borrower from its seller, as evidenced by the seller's invoice to the Borrower.

11. HSBC Research November 5, 2024 Trust W o rking Capital Requirement Bank Instruments Receipts 137.23 217.04 Pte. Ltd.

Total 2,249.84 2,444.06 **This facility has been renewed.

For further details on the abovementioned borrowings, see “Financial Indebtedness –Principal terms of subsisting borrowings availed by our Company and our Subsidiaries” on page [●].

Details of our Wholly-Owned Subsidiaries and Step-Down Subsidiaries Set forth below are (i) certain key financial information, and (ii) the shareholding pattern of our Wholly-Owned Subsidiaries, namely, Translumina Therapeutics and Transhealth and our Step-Down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd.. and Research Instruments Pte. Ltd.

For further details, also see “History and Certain Corporate Matters – Our Subsidiaries” on page [●].

Translumina Therapeutics Key financial information 27Set forth below are key financial information of Translumina Therapeutics for the six months period ended June 30, 2026and the Financial Years ended March 31, 2026, March 31, 2025 and March 31, 2024:

(in ₹ million, unless otherwise stated) Particulars As at and for the As at and for As at and for As at and for three months Financial Year Financial Year Financial Year period ended June ended March 31, ended March 31, ended March 31, 30, 2026 2026 2025 2024 Equity share capital 0.10 0.10 0.10 Nil Preference share capital - Nil Nil Nil Revenue from operations 1,201.54 4,577.53 4,454.80 3,901.43 Other income 39.75 148.89 193.32 80.04 Total income 1,241.29 4,726.43 4,648.12 3,981.47 Restated profit for the period/year (16.33) 165.84 89.76 326.07 Revenue from operations as a 16.36 17.75 23.42% 25.12% percentage of consolidated revenue (in %) Reserves (excluding revaluation 431.80 443.41 286.88 342.74 reserves) Earnings per share (Basic) (face (146.43) 1,675.27 (2,852.07) NA value of ₹ 1) Earnings per share (Diluted) (face (146.43) 1,675.27 (2,852.07) NA value of ₹ 1) Total borrowings 2,520.99 2,216.68 2,518.50 859.79 Net worth 431.90 443.41 286.98 1,990.33 Net asset value 4,276.10 4,390.09 2,841.27 Nil

Note:

(1) Revenue from operations also corresponds to the total sales generated during the relevant financial period/year

(2) Restated profit for the period/year also corresponds to the profit after tax for the relevant financial period/year Shareholding pattern As on the date of this Draft Red Herring Prospectus, the shareholding pattern of Translumina Therapeutics is as

follows:

Name of the shareholder Number of equity shares of ₹ 1 each Percentage of shareholding (%) Our Company 100,001 99.01 Avnish Mehra* 999 0.99 Vishal Sharma* 1 Negligible Punita Sharma* 1 Negligible Vishal Omprakash Goenka* 1 Negligible Total 101,003 100.00 * As a nominee of our Company.

Transhealth Private Limited Key financial information Set forth below are key financial information of Transhealth Private Limited for the three months period ended June 30, 2026 and the Financial Years ended March 31, 2026, March 31, 2025 and March 31, 2024:

(in ₹ million, unless otherwise stated) Particulars As at and for the As at and for As at and for As at and for three months Financial Year Financial Year Financial Year period ended June ended March 31, ended March 31, ended March 31, 30, 2026 2026 2025 2024 Equity share capital 30.00 30.00 30.00 30.00 Preference share capital Nil Nil Nil Nil Revenue from operations 134.44 610.12 793.89 376.40 Other income 3.11 16.46 27.70 12.76 28Particulars As at and for the As at and for As at and for As at and for three months Financial Year Financial Year Financial Year period ended June ended March 31, ended March 31, ended March 31, 30, 2026 2026 2025 2024 Total income 137.55 626.58 821.59 389.16 Restated profit for the period/year 14.55 17.81 74.30 57.18 Revenue from operations as a 1.83 2.37 4.17 2.42 percentage of consolidated revenue (in %) Reserves (excluding revaluation 213.57 198.42 180.77 105.48 reserves) Earnings per share (Basic) (face 4.95 5.86 24.77 18.93 value of ₹ 10) Earnings per share (Diluted) (face 4.95 5.86 24.77 18.93 value of ₹ 10) Total borrowings 799.00 784.27 693.32 748.78 Net worth 243.57 228.42 210.77 135.48 Net asset value 81.19 76.14 70.26 45.16

Note:

(1) Revenue from operations also corresponds to the total sales generated during the relevant financial period/year

(2) Restated profit for the period/year also corresponds to the profit after tax for the relevant financial period/year As on the date of this Draft Red Herring Prospectus, the shareholding pattern of Transhealth Private Limited is as

follows:

Name of the shareholder Number of equity shares of ₹ 10 Percentage of shareholding (%) each Our Company 2,999,999 100.00 Vishal Sharma* 1 Negligible Total 3,000,000 100.00 *As nominee of our Company CPC Diagnostics Private Limited Key financial information Set forth below are key financial information of CPC Diagnostics Private Limited for the three months period ended June 30, 2026 and the Financial Years ended March 31, 2026, March 31, 2025 and March 31, 2024:

(in ₹ million, unless otherwise stated) Particulars As at and for the As at and for As at and for As at and for three months Financial Year Financial Year Financial Year period ended June ended March 31, ended March 31, ended March 31, 30, 2026 2026 2025 2024 Equity share capital 61.41 61.41 61.04 61.04 Preference share capital - - - - Revenue from operations 876.05 3,227.31 2,743.60 2,455.13 Other income 7.29 12.88 10.68 11.60 Total income 883.34 3,240.19 2,754.28 2,466.73 Restated profit for the period/year 59.98 126.34 143.61 95.11 Revenue from operations as a 11.93 12.52 percentage of consolidated revenue (in %) 14.42 15.81 Reserves (excluding revaluation 1,245.25 1,185.09 reserves) 1,057.30 951.22 Earnings per share (Basic) (face 97.67 206.30 value of ₹ 100) 235.27 155.82 Earnings per share (Diluted) (face 97.67 205.74 value of ₹ 100) 233.86 155.10 Total borrowings 479.68 539.14 319.87 196.41 Net worth 1,306.66 1,246.50 1,118.34 1,012.26 Net asset value 2,127.87 2,035.42 1,832.19 1,658.39

Note:

29(1) Revenue from operations also corresponds to the total sales generated during the relevant financial period/year

(2) Restated profit for the period/year also corresponds to the profit after tax for the relevant financial period/year As on the date of this Draft Red Herring Prospectus, the shareholding pattern of CPC Diagnostics Private Limited,

India is as follows:

Name of shareholder Number of equity shares of ₹ 100 each Percentage of shareholding (%) Everlife Holdings Pte. Ltd. 396,750 64.61 Our Company 65,196 10.62 Malini Kailasnath 42.969 7.00 Bhuvana Panchanath 39,412 6.42 Radhakrishnan Kailasnath 30,228 4.92 Radhakrishnan Panchanath 25,241 4.11 Pramod Kabra 4,028 0.66 Rohan Panchanath 2,100 0.34 K Ashwin Narayan 1,050 0.17 K Vivek Radhakrishnan 1,050 0.17 Gopinathan V. 910 0.15 Venkatasubramaniam Ramesh 910 0.15 Sivaramakrishnan C 840 0.14 P Naresh Kumar 532 0.09 K Hemadri 441 0.07 Alex Vizhalil Paul 406 0.07 Seshadhri S 350 0.06 U Srini 343 0.06 Gorle Ravi 255 0.04 Govindan S V 217 0.04 D Latha 210 0.03 D Sathish Kumar 168 0.03 T Anandh 140 0.02 Abhay Kumar 105 0.02 Sangeetha R 84 0.01 Raji Subbarayan 71 0.01 Mohideen Khan U 35 0.01 Srimika Pranav Khismatrao 28 Negligible Total 614,069 100.00

Note: Pursuant to the share purchase agreement dated February 24, 2026, the remaining 152,123 equity shares held by shareholders other than Everlife and the Company, will be transferred by September 30, 2026 or March 31, 2027 or any mutually decided date Chemopharm Sdn. Bhd.

Key financial information Set forth below are key financial information of Chemopharm Sdn. Bhd. for the three months period ended June 30, 2026 and the Financial Years ended March 31, 2026, March 31, 2025 and March 31, 2024:

(in ₹ million, unless otherwise stated) Particulars As at and for the As at and for As at and for As at and for three months Financial Year Financial Year Financial Year period ended June ended March 31, ended March 31, ended March 31, 30, 2026(1) 2026(2) 2025(2) 2024(3) Equity share capital 592.90 595.65 394.80 359.95 Preference share capital - - - - Revenue from operations 1,290.90 4,268.06 2,647.93 2,259.58 Other income 175.36 1,212.24 547.56 504.18 Total income 1,466.26 5,480.30 3,195.49 2,763.76 Restated profit for the period/year 259.86 1,245.63 431.28 227.09 Revenue from operations as a 17.58 16.55 13.92 14.55 percentage of consolidated revenue (in %) Reserves (excluding revaluation 4,057.75 3,820.32 2,030.09 1,446.16 reserves) 30Particulars As at and for the As at and for As at and for As at and for three months Financial Year Financial Year Financial Year period ended June ended March 31, ended March 31, ended March 31, 30, 2026(1) 2026(2) 2025(2) 2024(3) Earnings per share (Basic) 43.83 210.03 75.87 39.94 Earnings per share (Diluted) 43.83 210.03 72.67 38.33 Total borrowings 5,743.99 5,888.84 4,823.18 4,305.43 Net worth 4,650.65 4,415.97 2,424.90 1,806.12 Net asset value 784.38 744.80 426.87 317.94

(1) Calculated basis the exchange rate of MYR 1 = ₹ 23.23, as of June 30, 2026 and an average exchange rate of MYR 1 = ₹ 23.67 for the three months period ended June 30, 2026

(2) Calculated basis the exchange rate of MYR 1 = ₹ 23.34, as of March 31, 2026 and an average exchange rate of MYR 1 = ₹ 21.26 for the Financial Year ended March 31, 2026

(3) Calculated basis the exchange rate of MYR 1 = ₹ 19.32 as of March 31, 2025 and an average exchange rate of MYR 1 = ₹ 18.78 for the Financial Year ended March 31, 2025

(4) Calculated basis the exchange rate of MYR 1 = ₹ 17.61, as of March 31, 2024 and an average exchange rate of MYR 1 = ₹ 17.83 for the Financial Year ended March 31, 2024

Note:

(1) Revenue from operations also corresponds to the total sales generated during the relevant financial period/year

(2) Restated profit for the period/year also corresponds to the profit after tax for the relevant financial period/year As on the date of this Draft Red Herring Prospectus, the shareholding pattern of Chemopharm Sdn. Bhd. is as

follows:

Name of the shareholder Number of ordinary shares having Percentage of shareholding (%) no par value Everlife Holdings Pte. Ltd. 5,929,099 100.00 Ooi Chuai Aun 1 Negligible Total 5,929,100 100.00 Research Instruments Pte. Ltd.

Key financial information Set forth below are key financial information of Research Instruments Pte. Ltd. for the three months period ended June 30, 2026 and the Financial Years ended March 31, 2026, March 31, 2025 and March 31, 2024:

(in ₹ million, unless otherwise stated) Particulars As at and for the As at and for As at and for As at and for three months Financial Year Financial Year Financial Year period ended June ended March 31, ended March 31, ended March 31, 30, 2026(1) 2026(2) 2025(3) 2024(4) Equity share capital 146.11 145.96 25.54 24.74 Preference share capital 0.00 0.00 - - Revenue from operations 542.69 1,840.55 1,469.23 1,342.62 Other income 0.30 0.50 1.31 5.97 Total income 542.99 1,841.05 1,470.54 1,348.59 Restated profit for the period/year 73.86 217.63 165.80 200.38 Revenue from operations as a 7.39 7.14 percentage of consolidated revenue (in %) 7.72 8.64 Reserves (excluding revaluation reserves) 338.10 301.35 322.72 304.92 Earnings per share (Basic) 36.93 235.07 414.50 500.96 Earnings per share (Diluted) 36.93 235.07 414.50 500.96 Total borrowings 137.23 124.28 174.54 164.93 Net worth 484.21 447.31 348.26 329.66 Net asset value 242.11 223.65 870.66 824.15

(1)Calculated basis the exchange rate of SGD 1 = ₹ 73.06, as of June 30, 2026 and an average exchange rate of SGD 1 = ₹ 73.95 for the three months period ended June 30, 2026

(2) Calculated basis the exchange rate of SGD 1 = ₹ 72.98 as of March 31, 2026 and an average exchange rate of SGD 1 = ₹ 68.53 for the Financial Year ended March 31, 2026

(3) Calculated basis the exchange rate of SGD 1 = ₹ 63.86 as of March 31, 2025 and an average exchange rate of SGD 1 = ₹ 63.17 for the Financial Year ended March 31, 2025 31(4) Calculated basis the exchange rate of SGD 1 = ₹ 61.86, as of March 31, 2024 and an average exchange rate of SGD 1 = ₹ 61.56 for the Financial Year ended March 31, 2024

Note:

(1) Revenue from operations also corresponds to the total sales generated during the relevant financial period/year

(2) Restated profit for the period/year also corresponds to the profit after tax for the relevant financial period/year As on the date of this Draft Red Herring Prospectus, the shareholding pattern of Research Instruments Pte. Ltd. is

as follows:

Name of the shareholder Number of ordinary shares of SGD Percentage of shareholding (%) 1 each Chemopharm Sdn. Bhd. 2,000,000 100.00 Total 2,000,000 100.00 As of the date of this Draft Red Herring Prospectus, except as set out below, none of our Subsidiaries whose outstanding borrowings are proposed to be repaid/prepaid from the Net Proceeds have obtained credit rating from any recognised rating agency, either in India or abroad:

Subsidiary Instrument type Date Rating CPC Diagnostics Private Long term fund based cash March 30, 2026 [ICRA]BBB+ (Stable):

Limited credit, term loan, overdraft Reaffirmed facilities and long term unallocated limits Short term interchangeable [ICRA] A2; Reaffirmed limits The extent of the borrowings proposed to be prepaid and/or repaid as mentioned in the table above, is not determined and the repayment/ prepayment of the loans shall be based on various factors, including (i) any conditions attached to the borrowings restricting our ability to prepay the borrowings and time taken to fulfil such requirements, (ii) levy of any prepayment penalties and the quantum thereof, (iii) provisions of any law, rules, regulations governing such borrowings, and (iv) other commercial considerations including, among others, the interest rate on the loan facility, the amount of the loan outstanding and the remaining tenor of the loan.

Prepayment penalty or premium, if any, and other related costs shall be made by us out of the Net Proceeds.

Further, none of the borrowing have been availed from the related parties of our Company or been used for inter- group loans that could result in the indirect utilisation of the Net Proceeds for intra-group funding.

Our Company has obtained consents / no objection certificates, to the extent applicable, from the lenders whose borrowings are proposed to be repaid and/or prepaid by our Wholly Owned Subsidiaries and our Step-Down Subsidiaries.

Mode of Investment in the Wholly Owned Subsidiaries and the Step-Down Subsidiaries Pursuant to the resolution of our Board dated October 19, 2026, our Company shall deploy the amount of Net Proceeds allocated towards the repayment of certain loans of the abovementioned Wholly Owned Subsidiaries and the abovementioned Step-Down Subsidiaries in the form of equity or debt investments, details of which are

set forth below:

Investment by way of equity Our Company shall deploy a portion of the Net Proceeds aggregating up to ₹ 3,655.90 million, in one or more tranches, by way of subscription of fully paid-up equity instruments in Everlife Holdings. The board of directors of Everlife Holdings, pursuant to its resolution dated October 18, 2026, has taken on record such investment.

1. Everlife Holdings shall thereafter utilise the amount to invest into the abovementioned Step-Down Subsidiaries, namely, Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd, by way of extending loan facilities/ debt investments, details of which set forth below:

Term Particulars 32Chemopharm Sdn. Bhd.

Interest 5.82% p.a.

Security Unsecured Terms of repayment Upon demand by Everlife Holding Research Instruments Pte. Ltd Interest 3.00% p.a Security NA Terms of repayment Repayment within 60 months, unless mutually agreed to extend at the same terms The board of directors of Everlife Holdings, pursuant to its resolution dated October 18, 2026 has authorised the deployment of ₹ 3,438.86 million into Chemopharm Sdn. Bhd. and ₹ 217.04 million into Research Instruments Pte. Ltd. through debt. Further, each of the boards of directors of Chemopharm Sdn. Bhd. and Research Instruments Pte. Ltd, pursuant to their resolutions dated October 18, 2026 and October 18, 2026, respectively, have approved the availing of loan facility(ies) from Everlife Holdings, where the funds from such loan facility(ies) shall be utilised for the purposes of repaying/prepaying certain of their borrowings.

2. Our Company shall deploy a portion of the Net Proceeds aggregating up to ₹ 733.76 million and ₹ 204.98 million, respectively, in one or more tranches, by way of subscription of fully paid-up equity instruments in Translumina Therapeutics and Transhealth. The boards of directors of Translumina Therapeutics and Transhealth, pursuant to their resolutions dated October 17, 2026 and October 17, 2026, respectively, have passed an enabling resolution for the issuance of equity shares to our Company pursuant to the infusion of funds, where such funds shall be utilised for the purposes of repaying/prepaying certain of their borrowings.

Investment by way of debt Our Company shall deploy a portion of the Net Proceeds aggregating up to ₹ 503.87 million, in one or more tranches, by way of extending loan facility/ debt investment in our Step-Down Subsidiaries, namely, CPC Diagnostics Private, details of which set forth below:

Term Particulars CPC Diagnostics Private Limited Interest 10% p.a.

Security Unsecured Terms of repayment Repayment in give years from the date of disbursement of the first tranche, unless extended Subordination First priority over any other unsecured liabilities of CPC Diagnostics The boards of directors of CPC Diagnostics, pursuant to its resolutions dated October 16, 2026, has passed an enabling resolution for availing loan facility (ies) from our Company, where the funds from such loan facility(ies) shall be utilised for the purposes of repaying/prepaying certain of their borrowings.

Further, for all investments by way of debt, it is clarified that the Company will recover the principal amount with applicable interest, in accordance with the terms and conditions of the investments, as detailed above, for applicable Wholly-Owned Subsidiaries and Step-Down Subsidiaries. Such amount will subsequently be used by the Company for business purposes in accordance with applicable laws, which will include the following working capital purposes, organic capital expenditure that the Company may undertake. Everlife Holdings, Translumina Therapeutics and Transhealth, do not have any stated dividend policy and our Company cannot be assured of any dividends from such investment. Our Company will remain interested in our Wholly Owned Subsidiaries and our Step-Down Subsidiaries to the extent of our shareholding (direct or indirect, as applicable), and as a lender to whom funds have been deployed by way of debt.

While ICICI Bank Limited (“ICICI Bank”) is an affiliate of ICICI Securities Limited, one of our BRLMs and Citibank N.A and Citi Bank Limited (collectively, “Citibank”) are affiliates of Citigroup Global Markets India Private Limited, also one of our BRLMs, ICICI Bank and Citibank are not associates of our Company, our Wholly Owned Subsidiaries or our Step-Down Subsidiaries, in terms of the Securities and Exchange Board of India (Merchant Bankers) Regulations, 1992 and such loans have been sanctioned to our Wholly Owned Subsidiaries and our Step-Down Subsidiaries (as applicable) as part of the normal commercial lending activity by ICICI Bank and Citibank. Accordingly, we do not believe that there is any conflict of interest under the Securities and Exchange Board of India (Merchant Bankers) Regulations, 1992, as amended, or any other applicable SEBI rules 33or regulations. Please also see, “Risk Factors – A portion of the Net Proceeds may be utilized for the repayment/ prepayment, in full or in part, of certain outstanding borrowings availed by our certain Subsidiaries from lenders who are affiliates of our BRLMs.” on page [●].

2. General corporate purposes The Net Proceeds will first be utilized for the Object as set out above. Our Company intends to deploy any balance left out of the Net Proceeds towards general corporate purposes, as approved by our management, from time to time, subject to such utilization for general corporate purposes not exceeding 25% of the Gross Proceeds, in compliance with the SEBI ICDR Regulations.

Such general corporate purpose may include, but not limited to meeting expenses incurred in the ordinary course of business such as strategic initiatives, including growth opportunities, meeting expenses for research and development and meeting general corporate exigencies and contingencies and any other business requirements, along with any other purpose as may be approved by our Board or a duly appointed committee from time to time, subject to compliance with necessary provisions of the Companies Act, 2013.

The allocation or quantum of utilization of funds towards the specific purposes described above will also be determined by our Board, based on our business requirements and other relevant considerations, from time to time, subject to compliance with necessary provisions of the Companies Act, the SEBI ICDR Regulations, the SEBI Listing Regulations and other applicable laws. Our management, in accordance with the policies of the Board, shall have the flexibility in utilising surplus amounts, if any. In the event that our Company is unable to utilise the entire amount that our Company has currently estimated for use out of Net Proceeds in a given Fiscal, our Company will utilise such unutilised amount in the next Fiscal.

Interim use of Net Proceeds Pending utilization of the Net Proceeds for the purposes described above, our Company undertakes to deposit the Net Proceeds only in one or more scheduled commercial banks included in the Second Schedule of the Reserve Bank of India Act, 1934, as amended, as may be approved by our Board. In accordance with Section 27 of the Companies Act, our Company confirms that it shall not use the Net Proceeds for buying, trading or otherwise dealing in shares of any other listed company or for any investment in the equity markets.

Appraising entity None of the Objects require appraisal from, or have been appraised by, any bank/ financial institution/ any other agency, in accordance with applicable law.

Bridge financing Our Company has not raised any bridge loans from any bank or financial institution as on the date of this Draft Red Herring Prospectus, which are proposed to be repaid from the Net Proceeds.

Offer expenses The total Offer related expenses are estimated to be approximately ₹ [●] million.

Other than: (i) the listing fees and fees and expenses of the statutory auditors only in relation to the routine statutory audit of our Company entities and expenses for any product or corporate advertisements consistent with past practice of our Company (other than the expenses relating to marketing and advertisements in connection with the Offer), which will be borne solely by our Company (to the extent not attributable to the Offer); and (ii) fees and expenses for counsel to the Promoter Selling Shareholder, if any, which shall be borne solely and directly by the Promoter Selling Shareholder, the Promoter Selling Shareholder agrees, to share the costs and expenses (excluding all applicable taxes except STT, which shall be solely borne by the Promoter Selling Shareholder) directly attributable to the Offer, all Offer Expenses including, among other things, filing fees, book building fees and other charges, fees and expenses of the SEBI, the Stock Exchanges, the RoC and any other Governmental Authority, advertising, printing, road show expenses, accommodation and travel expenses, fees and expenses of the Indian legal counsel to our Company and the Indian and international legal counsel to the BRLMs, fees and expenses of the statutory auditors of our Company entities, registrar fees and broker fees (including fees for procuring of applications), bank charges, fees and expenses (and related taxes) of the BRLMs (also Members of the Syndicate) Self Certified Syndicate Banks, other Designated Intermediaries and any other consultant, advisor 34or third party in connection with the Offer shall be borne by our Company and the Promoter Selling Shareholder in proportion to the number of Equity Shares proposed to be issued and Allotted by our Company through the Fresh Issue and the portion of Offered Shares proposed to be sold by the Promoter Selling Shareholder through the Offer for Sale, respectively, except as may be prescribed by the SEBI or any other regulatory authority.

In the event that the Offer is postponed or withdrawn or abandoned for any reason or the Offer is not successful or consummated, all costs and expenses with respect to the Offer which may have accrued up to the date of such postponement, withdrawal, abandonment or failure shall be shared amongst our Company and the Promoter Selling Shareholder, in proportion to the number of Equity Shares proposed to be issued and allotted by our Company in the Fresh Issue and the portion of Offered Shares proposed to be sold by the Promoter Selling Shareholder in the Offer for Sale, except as may be prescribed by the SEBI or any other regulatory authority.

However, expenses relating to the Offer for Sale may be paid by our Company on behalf of the Promoter Selling Shareholder in the first instance and the Promoter Selling Shareholder agrees that upon commencement of listing and trading of the Equity Shares on the Stock Exchanges pursuant to the Offer, each Promoter Selling Shareholder shall, reimburse our Company for such expenses in relation to the Offer paid by our Company on behalf of the Promoter Selling Shareholder in proportion to the Offered Shares directly from the Public Offer Account in the manner as may be set out in the Cash Escrow and Sponsor Banks Agreement.

The break-up for the estimated Offer expenses are as follows:

Activity Estimated expenses(1) As a % of total estimated As a % of Offer size(1) (₹ in million) Offer related expenses(1) BRLM’s fees (including brokerage and [●] [●] [●] selling commission) Commission/processing fee for SCSBs, [●] [●] [●] Sponsor Bank(s) and Bankers to the Offer.

Brokerage and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs(1)(2)(3) Fees payable to Registrar to the Offer [●] [●] [●] Fees payable to the other parties to the Offer, [●] [●] [●] including, Statutory Auditors, Independent Chartered Accountant, industry expert, practicing company secretary, and independent chartered engineer Advertising and marketing expenses for the [●] [●] [●] Offer Others [●] [●] [●] Listing fees, SEBI filing fees, upload fees, [●] [●] [●] BSE and NSE processing fees, book building software fees and other regulatory expenses Printing and stationery [●] [●] [●] Fees payable to legal counsel [●] [●] [●] Miscellaneous* [●] [●] [●] Total estimated Offer expenses [●] [●] [●] Offer expenses include applicable taxes, where applicable. Offer expenses will be finalised on determination of Offer Price and incorporated at the time of filing of the Prospectus. Offer expenses are estimates and are subject to change.

Selling commission payable to the SCSBs on the portion for RIBs and Non-Institutional Bidders which are directly procured and uploaded by the SCSBs, would be as follows:

Portion for RIBs* [●]% of the Amount Allotted (plus applicable taxes) Portion for Non-Institutional [●]% of the Amount Allotted (plus applicable taxes) Bidders* * Amount Allotted is the product of the number of Equity Shares Allotted and the Offer Price.

Selling Commission payable to the SCSBs will be determined on the basis of the bidding terminal id as captured in the Bid book of BSE or NSE.

No processing fees shall be payable by our Company and the Promoter Selling Shareholder to the SCSBs on the applications directly procured by them.

Processing fees payable to the SCSBs of ₹[●] per valid application (plus applicable taxes) for processing the Bid cum Application Form for Non-Institutional Bidders which are procured by the members of the Syndicate/sub- Syndicate/Registered Broker/RTAs/ CDPs and submitted to SCSB for blocking.

Brokerage, selling commission and processing/uploading charges on the portion for RIBs (using the UPI mechanism) and Non- 35Institutional Bidders which are procured by members of the Syndicate (including their sub-Syndicate Members), RTAs and CDPs or for using 3-in-1 type accounts- linked online trading, demat & bank account provided by some of the brokers which are members of Syndicate (including their sub-Syndicate Members) would be as follows:

Portion for RIBs [●]% of the Amount Allotted (plus applicable taxes) Portion for Non-Institutional Bidders [●]% of the Amount Allotted (plus applicable taxes) The Selling commission payable to the Syndicate / sub-Syndicate Members will be determined on the basis of the application form number / series, provided that the application is also bid by the respective Syndicate / sub-Syndicate Member. For clarification, if a Syndicate ASBA application on the application form number / series of a Syndicate / sub-Syndicate Member, is bid by an SCSB, the Selling Commission will be payable to the SCSB and not the Syndicate / sub-Syndicate Member.

In addition to the selling commission referred above, any additional amount(s) to be paid by our Company and the Promoter Selling Shareholder shall be as mutually agreed amongst the Book Running Lead Managers (also the Members of the Syndicate) , our Company and the Promoter Selling Shareholder before the opening of the Offer.

Uploading Charges payable to members of the Syndicate (including their sub-Syndicate Members), RTAs and CDPs on the applications made by RIBs using 3-in-1 accounts/Syndicate ASBA mechanism and Non-Institutional Bidders which are procured by them and submitted to SCSB for blocking or using 3-in-1 accounts/Syndicate ASBA mechanism, would be as follows: ₹ 10 plus applicable taxes, per valid application bid by the Syndicate (including their sub-Syndicate Members), RTAs and CDPs.

The selling commission and bidding charges payable to Registered Brokers, the RTAs and CDPs will be determined on the basis of the bidding terminal id as captured in the Bid Book of BSE or NSE.

Selling commission/ uploading charges payable to the Registered Brokers on the portion for RIBs and Non-Institutional Bidders which are directly procured by the Registered Broker and submitted to SCSB for processing, would be as follows:

Portion for RIBs* ₹ [●]per valid application (plus applicable taxes) Portion for Non-Institutional Bidders* ₹ [●]per valid application (plus applicable taxes) Uploading charges/ Processing fees for applications made by RIBs using the UPI Mechanism would be as under:

Members of the Syndicate / RTAs / CDPs ₹ [●] per valid application (plus applicable taxes) /Registered Brokers Sponsor Bank(s) ₹ [●] for applications made by UPI Bidders using the UPI mechanism*. The Sponsor Bank(s) shall be responsible for making payments to the third parties such as remitter bank, NPCI and such other parties as required in connection with the performance of its duties under the SEBI circulars, the Syndicate Agreement and other applicable laws.

* Based on valid applications All such commissions and processing fees set out above shall be paid as per the timelines in terms of the Syndicate Agreement and Cash Escrow and Sponsor Bank Agreement.

The processing fees for applications made by UPI Bidders using the UPI Mechanism may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation on compliance with SEBI ICDR Master Circular.

Monitoring of utilisation of funds In accordance with Regulation 41 of the SEBI ICDR Regulations, our Company shall appoint a Monitoring Agency for monitoring the utilisation of Gross Proceeds prior to the filing of the Red Herring Prospectus with the RoC, as the proposed Fresh Issue exceeds ₹ 1,000 million.

Our Audit Committee and the Monitoring Agency will monitor the utilisation of the Gross Proceeds and the Monitoring Agency shall submit the report required under Regulation 41(2) of the SEBI ICDR Regulations, on a quarterly basis, until such time as the Gross Proceeds have been utilised in full, which shall include item-by-item description for all the expense heads under each object of the Offer. Our Company undertakes to place the report(s) of the Monitoring Agency on receipt before the Audit Committee without any delay. Our Company will disclose and continue to disclose, the utilisation of the Gross Proceeds, including interim use under a separate head in our balance sheet for such Fiscals as required under applicable law, clearly specifying the purposes for which the Gross Proceeds have been utilised, till the time any part of the Gross Proceeds remains unutilised. Our Company will also, in its balance sheet for the applicable Fiscals, provide details, if any, in relation to all such Gross Proceeds that have not been utilised, if any, of such currently unutilised Gross Proceeds. Further, our Company, on a quarterly basis, shall include the deployment of Gross Proceeds under various expense heads, as applicable, in the notes to our quarterly consolidated results. Our Company will indicate investments, if any, of unutilised Gross Proceeds in the balance sheet of our Company for the relevant Fiscals subsequent to receipt of listing and trading approvals from the Stock Exchanges.

Pursuant to Regulation 32(3) and Part C of Schedule II, of the SEBI Listing Regulations, our Company shall, on a quarterly basis, disclose to the Audit Committee the uses and applications of the Gross Proceeds. The Audit Committee shall make recommendations to our Board for further action, if appropriate. The statement shall be certified by the Statutory Auditor of our Company. Furthermore, in accordance with Regulation 32(1) of the SEBI Listing Regulations, our Company shall furnish to the Stock Exchanges on a quarterly basis, a statement indicating category wise deviations/variations, if any, in the actual utilisation of the proceeds of the Gross Proceeds from the Objects as stated above. This information will also be published in newspapers simultaneously with the interim or annual financial results and explanation for such variation (if any) will be included in our Director’s report, after placing the same before the Audit Committee.

36Variation in Objects In accordance with the Companies Act, our Company shall not vary the Objects without being authorised to do so by our Shareholders by way of a special resolution through a postal ballot. In addition, the notice issued to our Shareholders in relation to the passing of such special resolution (“Postal Ballot Notice”) shall specify the prescribed details as required under the Companies Act and applicable rules. The Postal Ballot Notice shall simultaneously be published in the newspapers, one in English, one in Hindi, which is also the regional language of the jurisdiction where our Registered Office is located. In accordance with the Companies Act, our Promoters will be required to provide an exit opportunity to the Shareholders who do not agree to such proposal to vary the objects, subject to the provisions of the Companies Act and in accordance with such terms and conditions, including in respect of pricing of the Equity Shares, in accordance with our Articles of Association, the Companies Act and the SEBI ICDR Regulations. For risks arising out of variation in Objects, please see “Risk Factors - Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior Shareholders’ approval. Further, our funding requirements and deployment of the Net Proceeds of the Offer are based on management estimates and have not been independently appraised. Our management will have broad discretion over the use of the Net Proceeds ” on page [●].

Other confirmations The Promoter Selling Shareholder will receive the proceeds of the Offer for Sale. Except as disclosed in this

section, no part of the Net Proceeds will be paid by our Company as consideration to our Promoters, the Promoter Group, our Directors, or our KMPs and members of the Senior Management.

There are no existing or anticipated transactions in relation to utilisation of Net Proceeds with our Promoters, the Promoter Group, Group Companies, our Directors, our KMPs and Senior Management.

Except for our Wholly-Owned Subsidiaries and our Step-Down Subsidiaries (each as defined for the purposes of this section) whose loans are proposed to be repaid/prepaid from a portion of the Net Proceeds, none of our Subsidiaries, Associates, Group Companies, as applicable, shall receive a part of or whole of the Net Proceeds directly or indirectly.

Our Company has neither entered into nor has planned to enter into arrangement/ agreements with our Promoters, members of the Promoter Group, Directors, our Key Managerial Personnel, our Senior Management or our Group Companies in relation to the utilization of the Net Proceeds.

37DECLARATION I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts

(Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY ________________________________________ Annaswamy Vaidheesh Chairperson and Non-Executive Independent Director

Date: October 19, 2026

Place: Mumbai 38DECLARATION I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts

(Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY ________________________________________ Rajani Kesari Non- Executive Independent Director

Date: October 19, 2026

Place: Mumbai 39DECLARATION I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts

(Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY _______________________________________ Ramesh Subrahmanian Non- Executive Independent Director

Date: October 19, 2026

Place: Singapore 40DECLARATION I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts

(Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY ________________________________________ Gurmit Singh Chugh Non-Executive Director

Date: October 19, 2026

Place: Delhi 41DECLARATION I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts

(Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY ________________________________________ Avnish Mehra Non-Executive Nominee Director

Date: October 19, 2026

Place: Singapore 42DECLARATION I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts

(Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY ________________________________________ Punita Sharma Non-Executive Director

Date: October 19, 2026

Place: Delhi 43DECLARATION I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts

(Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY ________________________________________ Arjun Oberoi Non-Executive Nominee Director

Date: October 19, 2026

Place: Shanghai 44DECLARATION I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts

(Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY ________________________________________ Probir Das Executive Director and Group Chief Executive Officer

Date: October 19, 2026

Place: Kolkata 45DECLARATION I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts

(Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE DIRECTOR OF OUR COMPANY ________________________________________ Vishal Omprakash Goenka Non-Executive Nominee Director

Date: October 19, 2026

Place: Mumbai 46DECLARATION I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, or guidelines, or regulations issued by the Government of India or the rules, or guidelines, or regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be, have been complied with and no statement made in this Addendum is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts

(Regulation) Rules, 1957, the Securities and Exchange Board of India Act, 1992, or the rules made or the guidelines or regulations issued thereunder, as the case may be. I further certify that all statements in this Addendum are true and correct.

SIGNED BY THE CHIEF FINANCIAL OFFICER OF OUR COMPANY ________________________________________ Dev Kumar Tripathy

Date: October 19, 2026

Place: Gurugram 47DECLARATION We, Evercure Holdings Pte. Ltd., the Promoter Selling Shareholder, hereby confirm, certify and declare that all statements and undertakings specifically made or confirmed by us in this Addendum in relation to ourselves, as the Promoter Selling Shareholder and the Offered Shares, are true and correct. We assume no responsibility, for any other statements, disclosures and undertakings, including, any of the statements, disclosures or undertakings made or confirmed by or relating to the Company or any other person(s) in this Addendum.

Signed for an on behalf of Evercure Holdings Pte. Ltd. _____________________________

Name: Terence Gerard Gomes

Designation: Director

Date: October 19, 2026

Place: Singapore 48